<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":6983,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Marine Polymer Techs., Inc. v. HemCon, Inc., 672 F.3d 1350, 102 U.S.P.Q.2d 1161 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/97842979cc5469a61613094878bc7879'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/97842979cc5469a61613094878bc7879'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1HAE38003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HAE38003">Previous Result: <span>Bellard v. Gautreaux, 675 F.3d 454, 33 I...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1HAEJM003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HAEJM003">Next Result: <span>Rogers v. Hartford Life &amp; Accident Ins. ...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Marine Polymer Techs., Inc. v. HemCon, Inc., 672 F.3d 1350, 102 U.S.P.Q.2d 1161 (Fed. Cir. 2012), Court Opinion'>
Marine Polymer Techs., Inc. v. HemCon, Inc., 672 F.3d 1350, 102 U.S.P.Q.2d 1161 (Fed. Cir....
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Marine Polymer Techs., Inc. v. HemCon, Inc., 672 F.3d 1350, 102 U.S.P.Q.2d 1161 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1HAD4U003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Marine Polymer Techs., Inc. v. HemCon, Inc.</div>
<div class='displayCitation'>102 U.S.P.Q.2d 1161</div>
<div class='displayCitation'>2012 BL 67310</div>
<div class='displayCitation'>2012 BL 67351</div>
<div class='displayCitation'>672 F.3d 1350</div>
<div class='displayCitation'>bldp_686772_v2</div>
<div class='displayCitation'>bna a0d1e1h1x1</div>
<div class='displayCitation'>bna a0d1f6g8g1</div>
<div class='displayCitation'>wkffecase:25860687</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HAD4U003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Marine Polymer Techs., Inc. v. HemCon, Inc., 672 F.3d 1350, 102 U.S.P.Q.2d 1161 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Marine Polymer Techs., Inc. v. HemCon, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/97842979cc5469a61613094878bc7879/document/X1HAD4U003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HAD4U003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HAD4U003" /><input id="title" name="title" type="hidden" value="Marine Polymer Techs., Inc. v. HemCon, Inc., 672 F.3d 1350, 102 U.S.P.Q.2d 1161 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="97842979cc5469a61613094878bc7879" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HAD4U003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%39%37%38%34%32%39%37%39cc%35%34%36%39a%36%31%36%31%33%30%39%34%38%37%38bc%37%38%37%39%2Fdocument%2FX%31HAD%34U%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/97842979cc5469a61613094878bc7879/bcite/X1HAD4U003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/97842979cc5469a61613094878bc7879/bcite/X1HAD4U003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/97842979cc5469a61613094878bc7879/bcite/X1HAD4U003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/97842979cc5469a61613094878bc7879/related_content/X1HAD4U003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1694805983235";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">672 F.3d 1350</div>
<div class="cite" data-cite-type="ReporterOfDecisions">102 U.S.P.Q.2d 1161</div>
<div class="cite" data-cite-type="DocketNumber">2010-1548</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 67351</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
MARINE POLYMER TECHNOLOGIES, INC., Plaintiff-Appellee, v. HEMCON, INC.,
Defendant-Appellant.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2010-1548.
</center></p>
<p><center>
March 15, 2012.
</center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_907812" href="#headnote_ref_pq2-dec_907812">[1]</a> <span>Patent construction &mdash; Claims &mdash; Broad or narrow </span> <a href="http://www.bloomberglaw.com/document/1694805983235/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=125.1303" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="125.1303">&#9658;125.1303</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnote_text">
Claim directed to &ldquo;biocompatible&rdquo;
composition of polymer that accelerates hemostasis is properly construed to require that polymer exhibit &ldquo;no detectable biological reactivity as determined by biocompatibility tests,&rdquo; even though several dependent claims permit non-zero scores on particular biocompatibility test, since specification teaches that polymer &ldquo;of the invention&rdquo;
has high degree of biocompatibility and summarizes test results as showing that claimed polymer &ldquo;exhibits no detectable biological reactivity,&rdquo; and since claim differentiation is overcome where, as here, contrary construction is dictated by written description;
federal district court's judgment of infringement, which is based on this claim construction, is therefore affirmed.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">REMEDIES</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_907813" href="#headnote_ref_pq2-dec_907813">[2]</a> <span>Monetary &mdash; Damages &mdash; Patents &mdash; Reasonable royalty </span> <a href="http://www.bloomberglaw.com/document/1694805983235/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=510.0507.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="510.0507.03">&#9658;510.0507.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Jury properly relied on entire market value rule in awarding damages for infringement of plaintiff's patent, and its award of approximately $30 million was reasonable and supported by substantial evidence, since use of entire market value as royalty base is acceptable if plaintiff shows that patent-related feature is basis for customer demand, since plaintiff's patent is directed to &ldquo;biocompatible p-GlcNAc&rdquo; used to accelerate hemostasis of serious wounds, and district court correctly found substantial evidence in record pertaining to importance of biocompatible p-GlcNAc in defendant's infringing products and its significance for market demand, and since jury was entitled to evaluate conflicting evidence and credit testimony of plaintiff's expert over that of defendant's expert in calculating its award.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_907814" href="#headnote_ref_pq2-dec_907814">[3]</a> <span>Practice and procedure in Patent and Trademark Office &mdash;
Re-examination &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1694805983235/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=110.1501" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="110.1501">&#9658;110.1501</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Infringement &mdash; Defenses &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1694805983235/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1101" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1101">&#9658;120.1101</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Plain and unambiguous language of 35 U.S.C. &sect;307(b)
provides that ex parte patent reexamination can give rise to intervening rights, but only with respect to &ldquo;amended or new&rdquo; claims incorporated into patent during reexamination, and &ldquo;amended,&rdquo;
for purposes of Section 307(b), does not include disavowal or disclaimer of claim scope by argument alone; in present action for infringement of patent directed to &ldquo;biocompatible&rdquo; compositions of polymer that accelerates hemostasis, defendant is not entitled to intervening rights in claims remaining after reexamination, since claim cannot be &ldquo;amended&rdquo; for purposes of Section 307(b)
without changing claim language itself, and claims at issue contained identical language before and after reexamination, and since patentee's arguments to examiner and cancellation of other claims during reexamination did not &ldquo;amend&rdquo; remaining claims or make them &ldquo;new&rdquo;
for intervening rights purposes, regardless of whether reexamination affected their effective scope.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
  <span CLASS="page_no" data-cite="672 f 3d 1351" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1351" data-primary-citation="672 F.3d 1350">[*1351]</span> <span CLASS="page_no" data-cite="672 f 3d 1352" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1352" data-primary-citation="672 F.3d 1350">[*1352]</span> Appeal from the United States District Court for the
District of New Hampshire, Joseph A. DiClerico, Jr., <span CLASS="page_no" data-cite="672 f 3d 1353" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1353" data-primary-citation="672 F.3d 1350">[*1353]</span> J.

</p></div>
<div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]

</p></div></div>
<div id="para2" printdualcolumn="true"><p>
  Brian M. Poissant, Jones Day, of New York, NY, for
plaintiff-appellee on rehearing en banc. With him on the brief
were Julie M. Baher, Lynda Q. Nguyen and Ognian V. Shentov. Of
counsel was Gregory A. Castanias, of Washington, DC.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Raymond A. Kurz, Hogan Lovells U.S. LLP, of Washington, DC, for
defendant-appellant on rehearing en banc. With him on the brief
were Celine Jimenez Crowson and Keith B. O'Doherty.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Michael A. Gollin, Venable LLP, of Washington, DC, for amicus
curiae Bio-technology Industry Organisation on rehearing en
banc. With him on the brief were William D. Coston, Martin L.
Saad, Meaghan H. Kent and Fabian M. Koenigbauer.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Edward R. Reines, Weil, Gotshal &amp; Manges, LLP, of Redwood
Shores, CA, for amici curiae HewlettPackard Company, et al. on
rehearing en banc. With him on the brief was Nathan Greenblatt.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Matthew C. Phillips, Stoel Rives LLP, of Portland, OR, for
amicus curiae Intellectual Ventures Management LLC, on
rehearing en banc. With him on the brief were Nathan C.
Brunette and Matthew C. Rainey, Intellectual Ventures
Management, LLC, of Bellevue, Washington.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Mitchell G. Stockwell, Kilpatrick Townsend &amp; Stockton LLP,
of Atlanta, GA, for amicus curiae Jan K. Voda, M.D., on
rehearing en banc.
<span CLASS="page_no" data-cite="672 f 3d 1354" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1354" data-primary-citation="672 F.3d 1350">[*1354]</span> 
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Robert G. Sterne, Sterne, Kessler, Goldstein &amp; Fox,
P.L.L.C., of. Washington, DC, for amici curiae Soverain
Software LLC, et al., on rehearing en banc. With him on the
brief was Jon E. Wright.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Matthew J. Moore, Latham &amp; Watkins LLP, of Washington, DC,
for amici curiae Geico Corporation, et al. With him on the
brief were Julie M. Holloway and Adam M. Greenfield.
<span CLASS="page_no" data-cite="102 uspq 2d 1162" data-cite-type="ReporterOfDecisions" data-cite-pageno="1162" data-primary-citation="102 U.S.P.Q.2d 1161">[**1162]</span> </p></div>
<div id="para2" printdualcolumn="true"><p>
  Before RADER, Chief Judge, NEWMAN, LOURIE, BRYSON,
GAJARSA, <a HREF="#fn100" name="fnref_fn100">[fn1]</a> LINN, DYK, PROST, REYNA, and WALLACH, Circuit
Judges.<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> <i>Circuit Judge</i> GAJARSA assumed senior status on
July 31, 2011.
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> <i>Circuit Judges</i> MOORE and O'MALLEY did not
participate in the decision.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Opinion for the court in part filed by Circuit Judge LOURIE, in
which Chief Judge RADER and Circuit Judges NEWMAN, BRYSON, and
PROST join in full, and in which Circuit Judge LINN joins in
part II.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Opinion filed by Circuit Judge DYK, dissenting in part, in
which Circuit Judges GAJARSA, REYNA, and WALLACH join in full,
and in which Circuit Judge LINN joins in parts I &mdash; II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  LOURIE, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Defendant-Appellant HemCon, Inc. ("HemCon") appeals from a
judgment of the United States District Court for the District
of New Hampshire holding that HemCon infringed U.S. Patent
6,864,245 ("the &prime;245 patent") assigned to
Plaintiff-Appellee Marine Polymer Technologies, Inc. ("Marine
Polymer"). On September 26, 2011, a panel of this court
reversed the district court's decision, concluding that HemCon
had acquired intervening rights in the &prime;245 patent based
on actions taken by Marine Polymer during a parallel
reexamination proceeding. <i>Marine Polymer Techs., Inc. v.</i>
<i>HemCon, Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1GF9RA003?jcsearch=659%20F.3d%201084&amp;summary=yes#jcite">659 F.3d 1-1084</a> (Fed. Cir. 2011) ("<i>Panel</i>
<i>Opinion"), vacated</i>, ___ <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1H0NAM003?jcsearch=475%20Fed.%20Appx.%20315&amp;summary=yes#jcite">Fed.Appx. ___,</a> <a>2012 WL 255331</a>
(Fed. Cir. Jan. 20, 2012). Upon reconsideration en banc, we
affirm the judgment of the district court by an equally divided
court. Although the district court did not have the
reexamination before it or decide the effect of that issue on
its decision, we also consider HemCon's arguments with respect
to the reexamination and a majority of this court concludes as
an alternative ground for affirmance <span CLASS="page_no" data-cite="2012 bl 67351 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> that intervening rights do
not apply to claims that have not been amended and are not new.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Marine Polymer owns the &prime;245 patent, which discloses and
claims preparations of poly-&beta;-1&rarr;4-N-acetylglucosamine
("p-GlcNAc"), a naturally occurring polysaccharide polymer
produced by organisms such as arthropods, fungi, and
microalgae. Purified p-GlcNAc has utility in various
industrial, pharmaceutical, and bio-medical applications. For
example, p-GlcNAc promotes hemostasis (<i>i.e.</i>, stoppage
of bleeding or hemorrhage) and is therefore useful in trauma
units for treating serious wounds.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;245 patent places particular emphasis on
"biocompatible" compositions of p-GlcNAc. In this context,
biocompatibility relates to a compound's biological reactivity
or tendency to elicit deleterious reactions &mdash;
<i>e.g.</i>, necrosis, erythema, edema, cellular
degeneration-upon exposure to living cells or tissues.
<i>E.g.</i>, &prime;245 patent col.42 11.36-38, col.44
11.15-16. The specification describes four tests that can be
used to assess the biocompatibility of a substance: an elution
test, an implantation test, an intracutaneous injection test,
and I a systemic injection test. <i>Id.</i> col.42 11.1-3.
<span CLASS="page_no" data-cite="672 f 3d 1355" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1355" data-primary-citation="672 F.3d 1350">[*1355]</span> 
The disclosed elution test involves exposing a test
substance to a solution to create an extract, exposing cultured
test cells to the extract, and then observing the cells for
signs of cytotoxicity. <i>See id.</i> col.42 11.6-62. The
implantation test involves implanting a sample of the test
substance into an animal's muscle tissue and scoring the
severity of any adverse local reactions. <i>See id.</i>
col.42 l.64 &mdash; col.43 l.64. The intracutaneous injection
test calls for preparing an extract of the test substance,
injecting small volumes of the extract into the skin of an
animal, and monitoring the injection sites for reactivity.
<i>See id.</i> col.43 l.65 &mdash; col.44 l.56. Finally, in
the systemic injection test, animals are monitored for weight
changes and other overt signs of toxicity after receiving
intravenous or intraperitoneal injections of a test substance
extract. <i>See id.</i> col.44 l.57 &mdash; col.45 l.42.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In describing these biocompatibility tests, the specification
indicates that their requirements are met if a given test
substance shows no more than mild or slight reactivity. For
example, scores on the elution test range from zero to four on
a scale of biological reactivity, where zero represents no
reactivity, one represents slight reactivity, two represents
mild reactivity, and three or four represent moderate or severe
reactivity, respectively, and a substance can satisfy the
elution test "if none of the cultures treated with the test
article show a greater than mild reactivity." <i>Id.</i>
col.42 11.41-62. But with regard to the claimed p-GlcNAc
compositions, the specification also states that "the p-GlcNAc
of the invention exhibits no detectable biological reactivity,
as assayed by elution tests, intramuscular implantation in
rabbits, intracutaneous injection in rabbits, and systemic
injections in mice." <i>Id.</i> col.41 l.66 &mdash; col.42
l.3; <i>see also</i> col.45 l.44 &mdash; col.49 l.66
(reporting biocompatibility test results <span CLASS="page_no" data-cite="2012 bl 67351 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> for p-GlcNAc showing
zero reactivity on each test).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;245 patent issued with 22 claims, all of which
recite "biocompatible" compositions of p-GlcNAc. A majority of
those claims recite the "biocompatible" limitation generically.
Independent claim 6 is representative:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A <i>biocompatible</i>
  poly-&beta;-1&rarr;4-acetylglucosamine comprising up
  to about 150,000 N-acetylglucosamine monosaccharides
  covalently attached in a &beta;-1&rarr;4 conformation
  and having a molecular weight of up to about 30
  million daltons in which at least one
  N-acetylglucosamine monosaccharide has been
  deacetylated.
<span CLASS="page_no" data-cite="102 uspq 2d 1163" data-cite-type="ReporterOfDecisions" data-cite-pageno="1163" data-primary-citation="102 U.S.P.Q.2d 1161">[**1163]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Id.</i> col.72 11.5-10 (emphasis added). In addition, the
&prime;245 patent contains several dependent claims that recite
specific scores on the elution test. For example, claim 12
claims: "The biocompatible
poly-&beta;-1&rarr;4-N-acetylglucosamine of any one of claims
6-11 <i>which has an elution test score of or Id.</i> col.72
11.33-35 (emphasis added). Claims 3 and 20 also specify zero
scores on the elution test; analogous claims 4, 5, 13, 14, 21,
and 22 require elution test scores of one or two. <i>E.g.,</i>
<i>id.</i> col.72 11.33-41.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Marine Polymer sued HemCon in March 2006, alleging that HemCon
infringed the &prime;245 patent. During subsequent
<i>Markman</i> proceedings, Marine Polymer argued that
"biocompatible" p-GlcNAc should be construed to mean
"biomedically pure [p-GlcNAc] that reproducibly exhibits
acceptably low levels of adverse bioreactivity, as determined
by biocompatibility tests." <i>Marine Polymer Techs., Inc. v.</i>
<i>HemCon, Inc.</i>, <cite>No. 06-CV-100</cite>, [<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X18SNBG003?jcsearch=2008%20BL%2096692&amp;summary=yes#jcite">2008 BL 96692</a>], 2008 WL 1995454, at *1
(D.N.H. May 6, 2008). HemCon countered that "biocompatible"
should be read as limiting the claims to p-GlcNAc that had been
"harvested from plant microalgae," or, in the alternative,
should be interpreted broadly to mean "suited for biomedical
applications." <i></i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X18SNBG003?jcsearch=2008%20BL%2096692&amp;summary=yes#jcite">Id. at *1-2</a>. The district court
considered, and ultimately
<span CLASS="page_no" data-cite="672 f 3d 1356" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1356" data-primary-citation="672 F.3d 1350">[*1356]</span> 
rejected, each of the parties' proposed constructions after
reviewing the &prime;245 patent's claim language, written
description, and prosecution history. Instead, the district
court concluded that "biocompatible" p-GlcNAc, as claimed in
the &prime;245 patent, means p-GlcNAc "with low variability,
high purity, and no detectable biological reactivity as
determined by bio-compatibility tests." <i></i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X18SNBG003?jcsearch=2008%20BL%2096692&amp;summary=yes#jcite">Id. at *10</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Marine Polymer then moved for summary judgment that HemCon
literally infringed claims 6, 7, 10-12, 17, and 20 of the
&prime;245 patent. Applying its claim construction, the
district court granted Marine Polymer's motion and held that
HemCon had infringed all seven asserted claims. A jury trial
followed to determine validity and damages. The jury made
factual findings relating to obviousness and determined that
the &prime;245 patent was not anticipated by the cited prior
art. With respect to damages, the jury found that Marine
Polymer was entitled to a reasonable royalty of $29,410,246.
After the jury verdict, HemCon filed motions for judgment as a
matter of law ("JMOL") on anticipation, on the jury's factual
findings relating to obviousness, and challenging the damages
award as not supported by substantial evidence. The district
court denied each of the motions and made a further legal
determination that the asserted <span CLASS="page_no" data-cite="2012 bl 67351 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> claims were not obvious under
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEIVVE003?jcsearch=35%20U.S.C.%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>. The district court entered a permanent
injunction on September 16, 2010, barring HemCon from further
infringement of the asserted claims, and issued its final
judgment on September 22, 2010. HemCon appealed the decision to
this court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In August 2009, while the infringement litigation was still
before the district court, HemCon filed a request for <i>ex</i>
<i>parte</i> reexanimation of the &prime;245 patent in the United
States Patent and Trademark Office ("PTO"). HemCon's
reexamination request cited ten prior art references &mdash;
all of which, according to HemCon, raised substantial new
questions of patentability for the &prime;245 patent given the
construction of "biocompatible" adopted by the district court.
J.A. 40740-41. In response, the PTO granted HemCon's
reexamination request, initiated reexamination proceedings, and
issued a non-final office action on April 1, 2010.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> In this
first office action, the examiner adopted a construction of
"bio-compatible" different from the district court's,
concluding that under its broadest reasonable interpretation,
the term meant "low variability, high purity, and <i>little or</i>
<i>no</i> detectable reactivity." J.A. 39503 (emphasis added).
Noting that dependent claims 4, 5, 13, 14, 21, and 22 of the
&prime;245 patent required elution test scores of one or two
(corresponding to slight or mild reactivity on that test as
defined in the specification), the examiner explained that the
district court's construction requiring "no detectable
biological reactivity" conflicted with those claims, while his
interpretation avoided such inconsistency. The examiner then
rejected all of the original 22 claims as invalid under his
broader construction in light of the cited prior art. In so
doing, he relied primarily on three prior art references
&mdash; a scientific article (Sandford) and two patents
(Peniston and Malette) &mdash; finding that each reference
explicitly disclosed nearly all of the limitations of every
claim. With respect to the "biocompatible" limitation, the
examiner explained that any difference between the claimed
biocompatibility and that disclosed by Sandford, Peniston, and
Malette was "minor" and would have been obvious to a person of
ordinary skill in the art at the
<span CLASS="page_no" data-cite="672 f 3d 1357" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1357" data-primary-citation="672 F.3d 1350">[*1357]</span> 
time of the invention. J.A. 39507; <i>see also</i> 39517,
39522.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In response, Marine Polymer addressed "the improper dependency
noted by the Examiner" by cancelling all six claims that had
recited elution test scores of one or two (<i>i.e.</i>,
claims that expressly required at least some reactivity), while
leaving each of the remaining claims 1-3, 6-12, and 15-20
unaltered. Having deleted the inconsistent claims, Marine
<span CLASS="page_no" data-cite="102 uspq 2d 1164" data-cite-type="ReporterOfDecisions" data-cite-pageno="1164" data-primary-citation="102 U.S.P.Q.2d 1161">[**1164]</span> Polymer argued that "the [district court's] interpretation of
the term `biocompatible' should be adopted in this
reexamination" in view of various consistent teachings within
the specification. J.A. 37688-90. With all conflicting claims
cancelled, the examiner "agree[d] with the [district] court's
construction of the term biocompatible as derived from the
specification of the . . . &prime;245 patent." J.A. 39481.
Furthermore, the examiner withdrew all rejections <span CLASS="page_no" data-cite="2012 bl 67351 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> in view of
that narrower construction and confirmed the remaining claims
as patentable. <i>Id.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The PTO did not provide notice of its intent to
issue a reexamination certificate for the &prime;245
patent until November 3, 2010, after the district
court had entered final judgment in Marine Polymer's
infringement action. HemCon timely appealed from the district
court's judgment, and on November 18, 2010, a motions panel of
this court granted a stay of the damages award and permanent
injunction pending appeal. On March 29, 2011, the PTO issued
the final reexamination certificate ("&prime;245 Reexam.
Cert."), which cancelled dependent claims 4, 5, 13, 14, 21, and
22 and confirmed the patentability of claims 1-3, 6-12, and
15-20 in accordance with the examiner's decision. &prime;245
Reexam. Cert. col.2 11.1-6.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A panel of this court heard oral arguments in HemCon's appeal
from the district court's judgment on June 7, 2011, and issued
a decision on September 26, 2011, in which a majority reversed
the district court's judgment on infringement and vacated the
injunction and the damages award on grounds that HemCon had
acquired intervening rights during reexamination of the
&prime;245 patent. <i>Panel Opinion</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1GF9RA003?jcsearch=659%20f%203d%201&amp;summary=yes#jcite">659 F.3d at 1090-95</a>.
Marine Polymer petitioned for en banc rehearing, and on January
20, 2012, the full court granted Marine Polymer's petition for
rehearing and vacated the judgment of the panel. <i>Manne</i>
<i>Polymer Techs., Inc. v. HemCon, Inc.</i>, <cite>No. 2010-1548</cite>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1H0NAM003?jcsearch=475%20Fed.%20Appx.%20315&amp;summary=yes#jcite">___ Fed.Appx. ___,</a> <a>2012 WL 255331</a> (Fed. Cir. Jan. 20, 2012). For the
reasons described below, we now affirm the judgment of the
district court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   I.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                      <i>The District Court's Decision</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                 A. Jurisdiction and Standards of Review
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We have jurisdiction to entertain this appeal under
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEIMUG003?jcsearch=28%20U.S.C.%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1). We address claim construction as a matter of
law, which we review without formal deference on appeal,
although we give respect to the judgments of the district
courts. <i>Cybor Corp. v. FAS Techs., Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X4Q5NA?jcsearch=138%20f%203d%201448&amp;summary=yes#jcite">138 F.3d 1448</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X4Q5NA?jcsearch=138%20f%203d%201448&amp;summary=yes#jcite">1456</a> (Fed. Cir. 1998) (en banc). We review grants of
summary judgment <i>de novo</i>, reapplying the same standard
applied by the district court under Federal Rule of Civil
Procedure <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X144L4C003?jcsearch=Fed.%20R.%20Civ.%20P.%2056(a)&amp;summary=yes#jcite">56</a>(a). <i>Iovate Health Scis., Inc. v.</i>
<i>Bio-Engineered Supplements &amp; Nutrition, Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1C5BLQ003?jcsearch=586%20f%203d%201376&amp;summary=yes#jcite">586 F.3d 1376</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1C5BLQ003?jcsearch=586%20f%203d%201376&amp;summary=yes#jcite">1380</a> (Fed. Cir. 2009). Our review of a district court's
denial of JMOL is governed by regional circuit law, <i>Union</i>
<i>Carbide Chems. &amp; Plastics Tech. Corp. v. Shell Oil</i>
<i>Co.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X13A2S6003?jcsearch=425%20f%203d%201366&amp;summary=yes#jcite">425 F.3d 1366</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X13A2S6003?jcsearch=425%20f%203d%201366&amp;summary=yes#jcite">1372</a> (Fed. Cir. 2005), and the First
Circuit reviews a district court's denial of JMOL <i>de novo,</i>
<i>Astro-Med, Inc. v. Nihon Kohden Am., Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1C0QRE003?jcsearch=591%20f%203d%201&amp;summary=yes#jcite">591 F.3d 1</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1C0QRE003?jcsearch=591%20f%203d%201&amp;summary=yes#jcite">13</a>
(1st Cir. 2009). In such situations, "a jury's verdict must be
upheld unless the facts and inferences, viewed in
<span CLASS="page_no" data-cite="672 f 3d 1358" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1358" data-primary-citation="672 F.3d 1350">[*1358]</span> 
the light most favorable to the verdict, point so strongly
and overwhelmingly in favor of the movant that a reasonable
jury could not have reached the verdict." <i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1C0QRE003?jcsearch=591%20F.3d%201&amp;summary=yes#jcite">Id</a>.</i> (quoting
<i>Borges Colon v. Roman-Abreu</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X143VT8003?jcsearch=438%20f%203d%201&amp;summary=yes#jcite">438 F.3d 1</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X143VT8003?jcsearch=438%20f%203d%201&amp;summary=yes#jcite">14</a> (1st
Cir. 2006)). In reviewing a district court's denial of JMOL on
damages, the First Circuit reverses only where "reasonable
persons could not have reached the conclusion that the jury
embraced." <i>Visible Sys. Corp. v. Unisys Corp.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1AACPA003?jcsearch=551%20f%203d%2065&amp;summary=yes#jcite">551 F.3d 65</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1AACPA003?jcsearch=551%20f%203d%2065&amp;summary=yes#jcite">74</a> (1st Cir. 2008) (quoting <i>Attrezzi, LLC v. Maytag</i>
<i>Corp.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1422KM003?jcsearch=436%20f%203d%2032&amp;summary=yes#jcite">436 F.3d 32</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1422KM003?jcsearch=436%20f%203d%2032&amp;summary=yes#jcite">37</a> (1st Cir. 2006)). Statutory
interpretation is a matter of law that we consider <i>de novo.</i>
<i>Aristocrat Techs. Austl. Pty Ltd. v. Int'l Game Tech.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1AACNK003?jcsearch=543%20f%203d%20657&amp;summary=yes#jcite">543 F.3d 657</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1AACNK003?jcsearch=543%20f%203d%20657&amp;summary=yes#jcite">660</a> (Fed. Cir. 2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                          B. Claim <span CLASS="page_no" data-cite="2012 bl 67351 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> Construction
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  HemCon argues that the district court's construction of
"biocompatible" to mean "low variability, high purity, and no
detectable biological reactivity as determined by
biocompatibility tests" was erroneous and warrants reversal of
the judgment. In supporting this assertion, HemCon relies
primarily on the presence of the six dependent claims in the
original &prime;245 patent (eventually cancelled in
reexamination) that required elution test scores of one or two,
as well as passages in the written description characterizing
certain biocompatibility tests as being satisfied despite
detectable bioreactivity. HemCon therefore proposes a broader
alternative construction, "suitable for biomedical
applications," that it argues would better align with the
teachings in the specification and render the asserted claims
invalid.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We disagree. The district court's interpretation of
"biocompatible" is supported by intrinsic evidence, and we
therefore uphold that <span CLASS="page_no" data-cite="102 uspq 2d 1165" data-cite-type="ReporterOfDecisions" data-cite-pageno="1165" data-primary-citation="102 U.S.P.Q.2d 1161">[**1165]</span> construction. Our claim construction
analysis begins with the language of the claim itself, as it
would have been understood by a person of ordinary skill in the
art at the time of the invention. <i>Phillips v. AWH</i>
<i>Corp.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">415 F.3d 1303</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">1312-13</a> (Fed. Cir. 2005) (en banc)
(quoting <i>Vitronics Corp. v. Concepirono, Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3T99H?jcsearch=90%20f%203d%201576&amp;summary=yes#jcite">90 F.3d 1576</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3T99H?jcsearch=90%20f%203d%201576&amp;summary=yes#jcite">1582</a> (Fed. Cir. 1996) ("we look to the words of the claims
themselves . . . to define the scope of the patented
invention")). Faced with widely varying proposed definitions
from the parties, the district court did not find that
"biocompatible" had a plain and ordinary meaning to one skilled
in the art. The district court properly looked first to the
claims of the &prime;245 patent and determined that they "do
not define `biocompatible.'" <i>Marine Polymer</i>,
[<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X18SNBG003?jcsearch=2008%20BL%2096692&amp;summary=yes#jcite">2008 BL 96692</a>], 2008 WL 1995454, at *3.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although several of the dependent claims specify that the
"biocompatible" p-GlcNAc may exhibit mild reactivity in an
elution test (<i>i.e.</i>, "an elution test score of 1" or
"an elution test score of 2"), the majority of the claims use
the term "bio-compatible" generically, without any reference to
a biocompatibility test score. Because the term "biocompatible"
admits of no limitation based on the context of the claims, the
district court properly turned to the teachings of the
specification.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_907812" href="#headnote_pq2-dec_907812">[1]</a> The specification teaches that the p-GlcNAc "of the invention"
has "a high degree of biocompatibility" and directs the reader
to a portion of the specification that "demonstrates the high
biocompatibility of the p-GlcNAc of the invention." &prime;245
patent col.10 11.49-62. Further, the cited material provides
empirical test results showing that the p-GlcNAc of the
invention exhibited zero reactivity on each disclosed
bio-compatibility test, <i>id.</i> col.45 11.45-50, col.46
11.10-11 and 66-67, col.49 11.26-29, and summarizes the results
as follows: "[I]t is demonstrated that the p-GlcNAc of the
invention exhibits no detectable biological reactivity, as
assayed by elution tests, intramuscular implantation in
rabbits, intracutaneous injection in rabbits, and systemic
<span CLASS="page_no" data-cite="672 f 3d 1359" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1359" data-primary-citation="672 F.3d 1350">[*1359]</span> 
injections in mice." <i>Id.</i> col.4 11.66-col.42 l.3.
Thus, the specification supports the district court's claim
construction. <i>See, e.g., Netcraft <span CLASS="page_no" data-cite="2012 bl 67351 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> Corp. v. eBay, Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1A70EM003?jcsearch=549%20f%203d%201394&amp;summary=yes#jcite">549 F.3d 1394</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1A70EM003?jcsearch=549%20f%203d%201394&amp;summary=yes#jcite">1398</a> (Fed. Cir. 2008) ("[T]he common
specification's repeated use of the phrase `the present
invention' describes the invention as a whole. . . .");
<i>Verizon Servs. Corp. v. Vonage Holdings Corp.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X17NGJU003?jcsearch=503%20f%203d%201295&amp;summary=yes#jcite">503 F.3d 1295</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X17NGJU003?jcsearch=503%20f%203d%201295&amp;summary=yes#jcite">1308</a> (Fed. Cir. 2007) ("When a patent thus describes
the features of the `present invention' as a whole, this
description limits the scope of the invention."); <i>Honeywell</i>
<i>Int'l, Inc. v. ITT Indus., Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1592FM003?jcsearch=452%20f%203d%201312&amp;summary=yes#jcite">452 F.3d 1312</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1592FM003?jcsearch=452%20f%203d%201312&amp;summary=yes#jcite">1318</a>
(Fed. Cir. 2006) (limiting claims to a fuel filter where "the
written description refers to the fuel filter as `this
invention' or `the present invention'").<a HREF="#fn400" name="fnref_fn400">[fn4]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  HemCon's arguments highlighting an inconsistency between the
district court's construction and the claims requiring non-zero
elution test scores, while not baseless, essentially amount to
a conflict between teachings in the specification and the
doctrine of claim differentiation. As we have held, claim
differentiation is "not a hard and fast rule and will be
overcome by a contrary construction dictated by the written
description or prosecution history." <i>Seachange Int'l Inc.</i>
<i>v. C-COR, Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12GCDM003?jcsearch=413%20f%203d%201361&amp;summary=yes#jcite">413 F.3d 1361</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12GCDM003?jcsearch=413%20f%203d%201361&amp;summary=yes#jcite">1369</a> (Fed. Cir. 2005); see
<i>also Laitram Corp. v. Rexnord, Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3IMEB?jcsearch=939%20f%202d%201533&amp;summary=yes#jcite">939 F.2d 1533</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3IMEB?jcsearch=939%20f%202d%201533&amp;summary=yes#jcite">1538</a> (Fed. Cir. 1991) ("Claim differentiation is a guide, not a
rigid rule."). Such description appears in the specification
here, as indicated above.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We also find HemCon's focus on the possibility of nonzero
"passing" scores on the disclosed biocompatibility tests
un-persuasive. In describing "Materials and Methods" for the
four disclosed biocompatibility tests, the specification
indicates that, for example, test substances may "meet[] the
biocompatibility test if none . . . show a greater than mild
reactivity." &prime;<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X320O82218J?jcsearch=usp%206864245&amp;summary=yes#jcite">245 patent</a> col.42 11.42-44. But such
language appears only in generalized descriptions of these test
methods; when read as a whole, the specification makes clear
that the p-GlcNAc <i>of the invention</i> outperforms
baseline standards and shows "no detectable biological
reactivity as determined by biocompatibility tests." The
district court's construction of "biocompatible" as meaning
p-GlcNAc "with low variability, high purity, and no detectable
biological reactivity as determined by biocompatibility tests"
is therefore affirmed by an equally divided court.<a HREF="#fn500" name="fnref_fn500">[fn5]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                             <span CLASS="page_no" data-cite="102 uspq 2d 1166" data-cite-type="ReporterOfDecisions" data-cite-pageno="1166" data-primary-citation="102 U.S.P.Q.2d 1161">[**1166]</span> C. Infringement
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following its decision on claim construction, the district
court ruled on summary judgment that HemCon infringed claims 6,
7, 10-12, 17, and 20 of the &prime;245 patent. On appeal,
HemCon's non-infringement challenge regarding claims 6, 7, 10,
11, and 17 hinges entirely on its failed claim construction
arguments, and HemCon does not otherwise dispute its
infringement of these claims. With regard to claims 12 and 20,
HemCon raises an additional defense, arguing that the district
court lacked sufficient evidence to establish literal
infringement because HemCon's products allegedly cannot undergo
elution testing
<span CLASS="page_no" data-cite="672 f 3d 1360" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1360" data-primary-citation="672 F.3d 1350">[*1360]</span> 
as required by those claims. However, HemCon has waived
that argument by failing to raise it in opposing summary
judgment, and we therefore need not consider it here.
<i>Pandrol USA LP v. Airboss Ry. Prods., Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XADUDO?jcsearch=320%20f%203d%201354&amp;summary=yes#jcite">320 F.3d 1354</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XADUDO?jcsearch=320%20f%203d%201354&amp;summary=yes#jcite">1366-67</a> (Fed. Cir. 2003). Accordingly, we affirm the
district court's judgment regarding infringement of claims 6,
7, 10-12, 17, and <span CLASS="page_no" data-cite="2012 bl 67351 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> 20 by an equally divided court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               D. Damages
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, HemCon seeks to overturn the jury's award of
$29,410,246 in damages as unreasonable and not supported by
substantial evidence. Specifically, HemCon argues that Marine
Polymer's expert lacked a sufficient basis for his testimony on
what would constitute a reasonable royalty rate and that the
jury improperly relied on the entire market value for its
damages calculation. During trial, both parties presented
expert testimony on damages. Marine Polymer's expert testified
that, based on his evaluation of the case, a reasonable royalty
would range from about 26-34% of HemCon's infringing sales, and
he settled on 30%, or $29,410,246, as the appropriate award. In
contrast, HemCon's expert testified that 2-4% of all infringing
sales represented the correct range, concluding that Marine
Polymer's reasonable royalties would total $2,767,589.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_907813" href="#headnote_pq2-dec_907813">[2]</a> Both experts used the total sales of the accused products
containing the infringing biocompatible p-GlcNAc as the royalty
base. The use of the entire market value as the royalty base is
acceptable to the extent that the patent owner proves that "the
patent-related feature is the basis for customer demand."
<i>Lucent Techs., Inc. v. Gateway, Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1BMVCG003?jcsearch=580%20f%203d%201301&amp;summary=yes#jcite">580 F.3d 1301</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1BMVCG003?jcsearch=580%20f%203d%201301&amp;summary=yes#jcite">1336</a> (Fed. Cir. 2009) (internal quotations omitted). The district
court correctly found that the record contains substantial
evidence to support a damages award based on the entire market
value of HemCon's infringing products, including "evidence
pertaining to the importance of biocompatible p-GlcNAc in
HemCon's products and its significance for market demand."
<i>Marine Polymer Techs., Inc. v. HemCon, Inc.</i>,
<cite>No. 06-CV-100</cite>, [<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1DSUKC003?jcsearch=2010%20BL%20178711&amp;summary=yes#jcite">2010 BL 178711</a>], 2010 WL 3070201, at *4 (D.N.H. Aug. 3, 2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Ultimately, the jury was entitled to evaluate this conflicting
evidence and credit the testimony of Marine Polymer's expert
over that of HemCon, as it did. The jury also heard testimony
from witnesses for both parties, including HemCon's own
president, describing the claimed p-GlcNAc as "critical" to the
core hemostatic function of the accused products. In sum, based
on the evidence of record, the jury's damages award was
supported by substantial evidence. In such cases, we may not
"substitute [our] choice for that of the jury." <i>Brooktree</i>
<i>Corp. v. Advanced Micro Devices, Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3K0FA?jcsearch=977%20f%202d%201555&amp;summary=yes#jcite">977 F.2d 1555</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3K0FA?jcsearch=977%20f%202d%201555&amp;summary=yes#jcite">1580</a>
(Fed. Cir. 1992). The damages award is therefore affirmed by an
equally divided court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                           <i>Intervening Rights</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition, HemCon argues that the asserted claims of the
&prime;245 patent changed in scope during reexamination, HemCon
thereby acquired intervening rights in those claims, and the
district court's finding of infringement should therefore be
reversed. To support its intervening rights defense, HemCon
asserts that the district court's interpretation of
"biocompatible" incorrectly narrowed the term by requiring "no
detectable biological reactivity." According to HemCon, the
district court's construction conflicts not only with
statements in the written description, but also with the
presence of dependent claims reciting elution test scores of
one or two &mdash; claims that permit slight or mild reactivity
and were in the <span CLASS="page_no" data-cite="2012 bl 67351 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> original version of the &prime;245 patent that
was before the district court.
<span CLASS="page_no" data-cite="672 f 3d 1361" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1361" data-primary-citation="672 F.3d 1350">[*1361]</span> 
HemCon contends that "biocompatible," at least as
represented in the &prime;245 patent before reexamination,
therefore must have encompassed low, non-zero levels of
bioreactivity, so that the proper construction <i>at that</i>
<i>time</i> was necessarily broader than the district court's
interpretation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Next, HemCon argues that, by cancelling dependent claims 4, 5,
13, 14, 21, and 22 and persuading the examiner to adopt the
district court's construction of "biocompatible" during
reexamination, Marine Polymer effected a substantive change in
the scope of each remaining claim &mdash; essentially, from
allowing some reactivity in the originally issued claims to
permitting "no detectable biological reactivity" after
reexamination. Citing our decision in <span CLASS="page_no" data-cite="102 uspq 2d 1167" data-cite-type="ReporterOfDecisions" data-cite-pageno="1167" data-primary-citation="102 U.S.P.Q.2d 1161">[**1167]</span> <i>Laitram Corp. v. NEC</i>
<i>Corp.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X40T8K?jcsearch=163%20f%203d%201342&amp;summary=yes#jcite">163 F.3d 1342</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X40T8K?jcsearch=163%20f%203d%201342&amp;summary=yes#jcite">1346-47</a> (Fed. Cir. 1998), HemCon
argues that the key to intervening rights lies in determining
"whether the <i>scope</i> of the reexamined claims differs
from the original claims." Corrected Br. for
Defendant-Appellant at 37, <cite>2010 WL 5650491</cite>. HemCon thus
concludes that this perceived "substantive change" to the
surviving claims of the &prime;245 patent during reexamination
triggered intervening rights with respect to those claims.
Under HemCon's view, substantive change applies especially to
claims 6, 7, 10, 11, and 17, which, reciting no numerical
result in any biocompatibility test, are generic in that
respect. Furthermore, HemCon argues that even claims 12 and 20
were substantially changed in scope when the examiner adopted
the district court's construction of "biocompatible" during
reexamination, despite the fact that those claims have at all
times required an elution test score of zero (corresponding to
"no signs of cellular reactivity" on that test, &prime;245
patent col.42 11.39-40). HemCon argues that while claims 12 and
20 specified no reactivity on the <i>elution</i> test prior
to reexamination, they nevertheless covered products exhibiting
slight reactivity on <i>other</i> biocompatibility tests
until Marine Polymer successfully pressed the more restrictive
"no detectable biological reactivity" construction during
reexamination.<a HREF="#fn600" name="fnref_fn600">[fn6]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Marine Polymer disagrees and argues that intervening rights
cannot apply with respect to claims that have not been amended
or newly introduced in the reexamination proceeding.<a HREF="#fn700" name="fnref_fn700">[fn7]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The doctrine of intervening rights first developed as courts
recognized that permitting substantive changes to the scope of
patent claims through post-issuance procedures left "the door
. . . open for gross injustice" where a third party, having
already begun to make, use, or sell a given article, finds its
previously lawful activities rendered newly infringing under a
modified patent. <i>See Sontag Chain Stores Co. v. Nat'l Nut</i>
<i>Co.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=310%20us%20281&amp;summary=yes#jcite">310 U.S. 281</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=310%20us%20281&amp;summary=yes#jcite">293-95</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=60%20supreme%20court%20961&amp;summary=yes#jcite">60 S.Ct. 961</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=84%20l%20ed%201204&amp;summary=yes#jcite">84 L.Ed. 1204</a>
(1940). In such situations, the defendant "acquired at least a
right to continue to use the [articles] as if it held a license
therefor under the reissued patent." <i></i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=60%20S.Ct.%20961&amp;summary=yes#jcite">Id. at 294-95</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=60%20supreme%20court%20961&amp;summary=yes#jcite">60 S.Ct. 961</a> (quoting <i>Ashland Fire Brick Co. v. Gen.</i>
<i>Refractories Co.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3LJE0?jcsearch=27%20f%202d%20744&amp;summary=yes#jcite">27 F.2d 744</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3LJE0?jcsearch=27%20f%202d%20744&amp;summary=yes#jcite">746</a> (6th Cir. 1928)). With
respect to reissued patents, the concept of intervening rights
was <span CLASS="page_no" data-cite="2012 bl 67351 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> codified by the Patent Act of 1952, and the statute
provides for two types of intervening rights: (1) intervening
<span CLASS="page_no" data-cite="672 f 3d 1362" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1362" data-primary-citation="672 F.3d 1350">[*1362]</span> 
rights that abrogate liability for infringing claims added
to or modified from the original patent if the accused products
were made or used before the reissue, often referred to as
absolute intervening rights; and (2) intervening rights that
apply as a matter of judicial discretion to mitigate liability
for infringing such claims even as to products made or used
after the reissue if the accused infringer made substantial
preparations for the infringing activities prior to reissue,
often referred to as equitable intervening rights. <i>See</i>
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">35 U.S.C. &sect; 252</a> (2006). Intervening rights do not accrue,
however, where the accused product or activity infringes a
claim that existed in the original patent and remains "without
substantive change" after reissue. <i>Seattle Box Co. v.</i>
<i>Indus. Crating &amp; Packing, Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3J4QL?jcsearch=731%20f%202d%20818&amp;summary=yes#jcite">731 F.2d 818</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3J4QL?jcsearch=731%20f%202d%20818&amp;summary=yes#jcite">827-28</a>
(Fed. Cir. 1984).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although intervening rights originated as a defense against
patents modified through reissue procedures, the doctrine has
since been extended to the context of patent reexamination.
Pursuant to <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">35 U.S.C. &sect;&sect; 307</a>(b) and <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XO7C00003?jcsearch=35%20U.S.C.%20316(b)&amp;summary=yes#jcite">316</a>(b), respectively,
both <i>ex parte</i> and <i>inter partes</i> reexaminations
can give rise to intervening rights. For example, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">&sect; 307(b)</a>
provides as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Any proposed <i>amended or new</i> claim determined
  to be patentable and incorporated into a patent
  following a reexamination proceeding will have the
  same effect as that specified in <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">section 252</a> of this
  title for reissued patents on the right of any person
  who made, purchased, or used within the United States,
  or imported into the United States, anything patented
  by such proposed amended or new claim, or who made
  substantial preparation for the same, prior to
  issuance of a certificate under the provisions of
  <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(a)&amp;summary=yes#jcite">subsection (a)</a> of this section.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">35 U.S.C. &sect; 307</a>(b) (emphasis added).<a HREF="#fn800" name="fnref_fn800">[fn8]</a> Thus, after a
patent emerges from reexamination, the statute makes available
absolute and equitable intervening rights to the same extent
provided in the reissue statute, but only with respect to
"amended or new" claims in the reexamined patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With regard to HemCon's intervening rights argument, we must
first note that the reexamination <span CLASS="page_no" data-cite="102 uspq 2d 1168" data-cite-type="ReporterOfDecisions" data-cite-pageno="1168" data-primary-citation="102 U.S.P.Q.2d 1161">[**1168]</span> of the &prime;245 patent was
a separate and distinct proceeding that is not properly before
us on appeal. It did not conclude until after trial, so the
district court did not consider, nor could it have considered,
the reexamination in rendering its judgment. The panel noted
that the issue of intervening rights arose after the district
court judgment, but concluded that it had the discretion to
consider that issue on appeal because it was an event as to
which judicial notice is appropriate. Exercising that
discretion, the panel held that, in light of its reversal of
the district court's claim construction, HemCon is entitled to
intervening rights and that the district court's judgment of
infringement therefore must be reversed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_907814" href="#headnote_pq2-dec_907814">[3]</a> Although we reject the premise of HemCon's argument regarding
intervening rights &mdash; that the district court's claim
construction prior to reexamination of the <span CLASS="page_no" data-cite="2012 bl 67351 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> &prime;245 patent
was erroneous &mdash; we conclude, as an alternative ground for
decision, that even if the district court's claim construction
was erroneous, HemCon's intervening
<span CLASS="page_no" data-cite="672 f 3d 1363" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1363" data-primary-citation="672 F.3d 1350">[*1363]</span> 
rights argument must fail because it disregards the plain
and unambiguous language of &sect; 307(b). <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">Section 307(b)</a>
governs intervening rights arising from <i>ex parte</i>
reexamination and specifies that only "amended or new" claims
incorporated into a patent during reexamination "will have the
same effect as that specified in section 252," <i>i.e.</i>,
will be susceptible to intervening rights. HemCon ignores this
threshold statutory requirement and asks that we proceed
directly to the subsidiary "substantive change" analysis, which
derives from &sect; 252. <i>See Kaufman Co. v. Lantech,</i>
<i>Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X4ADEJ?jcsearch=807%20f%202d%20970&amp;summary=yes#jcite">807 F.2d 970</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X4ADEJ?jcsearch=807%20f%202d%20970&amp;summary=yes#jcite">975-77</a> (Fed. Cir. 1986) (explaining the
relationship between <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">&sect;&sect; 252</a> and <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">307(b)</a> and holding that
"identical," as used in <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">&sect; 252</a>, means "without substantive
change"). But under <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">&sect; 307(b)</a>, the first question when
assessing whether intervening rights arose from a reexamination
is whether the asserted claim is "amended or new"; if the
answer is no, that ends the inquiry. Only if the claim at issue
is new or has been amended may the court proceed to the second
step in the analysis and assess the substantive effect of any
such change pursuant to <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">&sect; 252</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Such a framework is consistent with our holding in
<i>Laitram.</i> There, our focus rested on whether the claims
had been substantively changed precisely because <i>the claims</i>
<i>had been changed</i> &mdash; there was no question that the
claims at issue had been amended in reexamination, so the
dispute centered on the second step in the intervening rights
analysis, <i>viz.</i>, whether those literal amendments to
the claim language had effected substantive changes in claim
scope. <i>See Laitram</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X40T8K?jcsearch=163%20f%203d%201342&amp;summary=yes#jcite">163 F.3d at 1344</a> ("The parties
dispute whether the scope of the original claims was
substantively changed following <i>several amendments made</i>
<i>during the reexamination</i> of the . . . patent.") (emphasis
added). In contrast, the patent claims asserted here against
HemCon were neither "new" nor "amended" &mdash; claims 6, 7,
10-12, 17, and 20 contained identical language before
<i>and</i> after reexamination. &prime;245 patent col.72
11.5-16, 25-35, 50-54, 60-61; &prime;245 Reexam. Cert. col.2
11.1-5. Whether or not Marine Polymer's arguments to the
examiner and cancellation of claims during reexamination may
have affected the remaining claims' effective scope, they did
not "amend" those claims for intervening rights purposes or
make them "new," which is what the statutory language requires.
Intervening rights are therefore unavailable under &sect; 307(b)
as a matter of law.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  HemCon sidesteps this issue by emphasizing the well-recognized
principle that arguments made during prosecution can affect the
ultimate meaning of a claim term &mdash; and thus the "scope"
of a claim &mdash; and then returning to its contention that
intervening rights turn on whether claim scope changes during
reexamination. HemCon thus posits that Marine Polymer's actions
in reexamination rendered the asserted claims effectively
"amended" by disavowal or estoppel, even though the language of
the claims was not formally changed. We disagree.
<span CLASS="page_no" data-cite="2012 bl 67351 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While it is true that claims are properly interpreted to
account for arguments and concessions made during prosecution,
HemCon's conclusion that the claims asserted here were
"amended" for purposes of &sect; 307(b) goes too far. In general
parlance, "amend" means "to alter . . . formally by adding,
deleting, or rephrasing." <i>American Heritage College</i>
<i>Dictionary</i> 42-43 (3d ed. 1997). And even if the term were
ambiguous standing alone, any doubts are resolved by its
context within &sect; 307.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Section 307(a) identifies three categories of claims in a
reexamined patent:
<span CLASS="page_no" data-cite="672 f 3d 1364" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1364" data-primary-citation="672 F.3d 1350">[*1364]</span> 
(1) claims that existed in the original patent but have
been cancelled as unpatentable, (2) claims that existed in the
original patent and have been confirmed as patentable, and (3)
amended or new claims that did not exist in the original patent
but have been found to be patentable and will be incorporated
into the patent by the PTO.<a HREF="#fn900" name="fnref_fn900">[fn9]</a> In providing for intervening
rights, &sect; 307(b) is limited <span CLASS="page_no" data-cite="102 uspq 2d 1169" data-cite-type="ReporterOfDecisions" data-cite-pageno="1169" data-primary-citation="102 U.S.P.Q.2d 1161">[**1169]</span> to the third category of
claims, as evidenced by its corresponding reference to any
"amended or new claim" that is "incorporated into a patent."
Any interpretation of "amended" that includes disavowal or
disclaimer by argument alone, as advocated by HemCon, would
conflict with the rest of &sect; 307, for it is difficult to
envision how arguments about claim meaning could be
"incorporated into a patent" by the Director of the PTO.
Finally, it is clear that "amended" is a term of art in patent
prosecution, <a HREF="#fn1000" name="fnref_fn1000">[fn10]</a> including reexamination proceedings, <a HREF="#fn1100" name="fnref_fn1100">[fn11]</a>
and in that context connotes formal changes to the actual
language of a claim. We thus cannot agree that a claim can be
"amended" for purposes of &sect; 307(b) without changing the
claim language itself.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  HemCon also expresses concern that excluding its concept of
amendment by argument from the ambit of &sect; 307(b) would
"create a significant loophole" in the intervening rights
defense &mdash; shrewd patentees would simply opt to rely on
arguments rather than amendments to effectively change, and
thereby preserve, otherwise invalid claims during reexamination
without engendering intervening rights against those claims.
Reply Br. for Defendant-Appellant at 25, <cite>2011 WL 287045</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We believe that is highly unlikely. If, in reexamination, an
examiner determines that particular claims are invalid and need
amendment to be allowable, one would expect an examiner to
require amendment rather than accept argument alone. Indeed,
Congress may well have expected that changes in claim scope
during reexamination would ordinarily be made by amendment,
which would avoid the risk of creating a loophole in the
intervening rights defense. Moreover, if an argument does
suffice to overcome a rejection, it is probably because the
claims at issue are not unallowable. Thus, the fear of
gamesmanship does not persuade us to rule contrary to the plain
meaning of the statute. Various amici have in fact pointed out
that such gamesmanship concerns run both ways, suggesting that
HemCon's interpretation of &sect; 307(b), if adopted, would
invite putative infringers to initiate reexamination
proceedings with marginal or noninvalidating prior <span CLASS="page_no" data-cite="2012 bl 67351 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> art. Under
HemCon's rule, such a requestor could expect that, even if
<span CLASS="page_no" data-cite="672 f 3d 1365" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1365" data-primary-citation="672 F.3d 1350">[*1365]</span> 
the reexamination ultimately confirms all claims as
patentable without amendment, the patent owner will necessarily
make substantive arguments in defending the claims, thereby
allowing the requestor to allege intervening rights based on
those arguments. In any event, we cannot and will not speculate
about possible consequences with respect to situations not
before us and which we cannot foresee.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dissent criticizes our discussion of HemCon's intervening
rights defense at length, asserting that this important issue
has been addressed only in dictum by the en banc court.
However, because the original opinion dealt extensively with
this issue, we must now decide the case as we find it and
clarify the law.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Regarding the clause in &sect; 307(b) restricting intervening
rights to "amended or new" claims, the dissent relies heavily
on analogy to other fields of law. While prior experience may
at times be helpful in statutory interpretation, references to
scattered permissive applications of the term "amended" to,
<i>e.g.</i>, a product safety regulation and a private
contract, are of limited utility in interpreting the specific
patent statute before us. Clear statutory language and the long
understanding of practitioners in a field trump interpretations
from other fields. Furthermore, the dissent selectively quotes
from amicus briefs arguing for a flexible interpretation of the
intervening rights statute, but other amici argue for giving
the statutory language its plain meaning. Clearly, nothing
conclusive can be gleaned from the amicus briefs, but we, in
addition to relying primarily on our own analysis, are more
persuaded by those arguing for a faithful reading of the
statutory text.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dissent makes a brief attempt to call upon the Supreme
Court to support its view, but the quoted language of the Court
was that a specification "be substantially changed, either by
the addition of new matter or the omission of important
particulars, so as to enlarge the scope of the invention as
originally claimed." <i>Russell v. Dodge</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1I0B?jcsearch=93%20us%20460&amp;summary=yes#jcite">93 U.S. 460</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1I0B?jcsearch=93%20us%20460&amp;summary=yes#jcite">463-64</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1I0B?jcsearch=23%20l%20ed%20973&amp;summary=yes#jcite">23 L.Ed. 973</a> (1876). Such language does not control
this case, which does not deal with the introduction of new
matter or the omission of important particulars so as to
enlarge the scope of the invention as originally claimed. <span CLASS="page_no" data-cite="102 uspq 2d 1170" data-cite-type="ReporterOfDecisions" data-cite-pageno="1170" data-primary-citation="102 U.S.P.Q.2d 1161">[**1170]</span> The
claims remaining in the patent are the same as originally
claimed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In sum, the plain directive of the governing statute before us
does not permit HemCon to invoke intervening rights against
claims that the PTO confirmed on reexamination to be patentable
as originally issued. To be sure, patent applicants' actions
and arguments during prosecution, including prosecution in a
reexamination proceeding, can affect the proper interpretation
and effective scope of their claims. But in rejecting HemCon's
request for intervening rights, we are not here interpreting
claims. Rather, we are interpreting a statute that provides for
intervening rights following reexamination only as to "amended
or new" claims. The asserted <span CLASS="page_no" data-cite="2012 bl 67351 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> claims of the &prime;245 patent
are neither.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, the final judgment of the district court is
<i>affirmed.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> <i>Ex parte</i> reexamination of the &prime;245 patent
was conducted under Reexamination Control No. 90/009,555.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Judge Dyk's opinion argues the details of claim
construction based on the assertion that neither party argued
the construction arrived at by the district court. We are not
bound by the arguments of the parties, however, and neither was
the district court. <i>Exxon Chetn. Patents, Inc. v. Lubrizol</i>
<i>Corp.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XAC7CK?jcsearch=64%20f%203d%201553&amp;summary=yes#jcite">64 F.3d 1553</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XAC7CK?jcsearch=64%20f%203d%201553&amp;summary=yes#jcite">1555</a> (Fed. Cir. 1995). Moreover, Judge
Dyk suggests that we are deciding claim construction based only
on one example, to the exclusion of others. In fact there is
only one example of the claimed p-GlcNAc in the specification;
the rest of the cited "examples" provide various methods of
purifying, characterizing, or using the disclosed product.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> We also note that, while not a basis for our affirmance,
the PTO arrived at the same conclusion upon interpreting the
term in its parallel reexamination proceeding.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> HemCon's position is supported by <i>amici curiae</i>
Hewlett-Packard Co., Broadcom Corp., Cisco Systems, Inc., Dell,
Inc., eBay, Inc., Facebook, Inc., Google Inc., and SAP America,
Inc.; and GEICO Corp., FedEx Corp., and Macy's, Inc.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> Marine Polymer's position is supported by <i>amici</i>
<i>curiae</i> Jan K. Voda; Intellectual Ventures Management LLC;
the Biotechnology Industry Association and Pharmaceutical
Research and Manufacturers of America; Soverain Software LLC
and Tessera, Inc.; and Sealy Corp.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XO7C00003?jcsearch=35%20U.S.C.%20%20316(b)&amp;summary=yes#jcite">Section 316(b)</a>, governing intervening rights available
after <i>inter partes</i> reexamination, contains essentially
identical language.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> The text of <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(a)&amp;summary=yes#jcite">Section 307(a)</a> reads as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In a reexamination proceeding under this chapter, when
  the time for appeal has expired or any appeal
  proceeding has terminated, the Director will issue and
  publish a certificate canceling any claim of the
  patent finally determined to be unpatentable,
  confirming any claim of the patent determined to be
  patentable, and incorporating in the patent any
  proposed amended or new claim determined to be
  patentable.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 307</a>(a) (2006).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> <i>See, e.g.</i>, 37 C.F.R. &sect; 1.121(c) ("All
claims being currently amended [shall] be submitted with
markings to indicate the changes that have been made relative
to the immediate prior version of the claims. . . . [A]dded
subject matter must be shown by underlining the added text. . . .
[D]eleted matter must be shown by strike-through. . . .");
<i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XB7IQU003?jcsearch=37%20C.F.R.%201.121(c)&amp;summary=yes#jcite">id</a>.</i> <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XMMVJ0003?jcsearch=37%20C.F.R.%201.114(c)&amp;summary=yes#jcite">&sect; 1.114(c)</a> (distinguishing between prosecution
arguments and amendments to the specification, claims, or
drawings).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> <i>See</i>, e.g., 37 C.F.R. &sect; 1.530(d) ("A
proposed amendment in an <i>ex parte</i> or an <i>inter</i>
<i>partes</i> reexamination proceeding is made by filing a paper
directing that proposed specified changes be made to the patent
specification, including the claims, or to the
drawings.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DYK, Circuit Judge, dissenting in part, with whom GAJARSA,
REYNA, and WALLACH, Circuit Judges, join in full, and with whom
LINN, Circuit Judge, joins in parts I-II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The court took this case en banc to address when absolute
intervening rights arise under <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">35 U.S.C. &sect; 307</a>(b) during
re-examination. In particular, the question is whether
intervening rights accrue when
<span CLASS="page_no" data-cite="672 f 3d 1366" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1366" data-primary-citation="672 F.3d 1350">[*1366]</span> 
the patentee limits the claim scope by argument rather than
by formal amendment to the claim language.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Despite the importance of the issue of intervening rights, as
evidenced by the amicus briefs filed by numerous companies and
organizations, the court did not seek further briefing and
argument by the parties. This approach to an important issue is
in my view difficult to justify. Now, remarkably, the court
having affirmed the district court's judgment by an equally
divided court, goes on to opine in dictum as to the issue of
intervening rights even though that issue (as discussed below)
has been resolved by the affirmance and also, in the majority's
view, "is not properly before us on appeal." Maj. Op. at 1362.
This is an unusual and unfortunate approach to an important
issue. This issue is likely to become even more important under
the new Leahy-Smith America Invents Act ("AIA") because of the
increased availability of reexamination. The majority's
interpretation of the statute is both incorrect and certain to
encourage improper strategic behavior by patent applicants. I
dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    I
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The starting point for an intervening rights determination is
the meaning of the original claim language. The district court
construed the key claim limitation ("biocompatiable") of the
original patent claims to require "polymers . . . with low
variability, high purity, and <i>no detectable biological</i>
<i>reactivity as determined by biocompatibility tests." Marine</i>
<i>Polymer Techs., Inc. v. HemCon, Inc.</i>, <cite>No. 06-cv-100-JD</cite>,
[<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X18SNBG003?jcsearch=2008%20BL%2096692&amp;summary=yes#jcite">2008 BL 96692</a>], 2008 WL 1995454, at *10 (D.N.H. May 6, 2008) (emphasis added).
Contrary to Judge Lourie's opinion, it seems to me that the
district court's construction was palpably incorrect and
inconsistent with our established claim construction
jurisprudence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Some background is essential to an understanding of the claim
construction issue. Marine Polymer asserted seven claims of
U.S. Patent No. 6,864,245 ("the &prime;245 patent"), directed
to p-GlcNAc polymers, against HemCon. Independent claim 6 is
representative and claims: "A <i>biocompatible</i> [p-GlcNAc
polymer] comprising up to about 150,000 N-acetylglucosamine
monosaccharides covalently attached in a &beta;-1&rarr;4
conformation and having a molecular weight of up to about 30
million daltons in which at least one N-acetylglucosamine
monosaccharide has been deacetylated." &prime;245 Pat. col.72
11.5-10 (emphasis added). Marine Polymer acknowledges that
p-GlcNAc polymers had been disclosed in the prior art. The
polymer also exists in nature in chitin, the chief organic
structural component in the cell walls of fungi or algae and
the protective shells of insects and crustaceans, but had been
difficult to isolate with high purity and low variability. The
&prime;245 patent purported to disclose for the first time a
"biocompatible" polymer in a purified form, <span CLASS="page_no" data-cite="2012 bl 67351 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> along with methods
for its purification from microalgae. With sufficient purity,
these polymers have a number of biomedical applications,
including, inter alia, as a means for the rapid control of
severe blood loss. A purified polymer provides "increased
effectiveness, reduced toxicity and improved bioavailability"
for its biomedical applications. <i>Id.</i> col.5 11.3-4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There are substantial questions as to whether the prior
art disclosed the claimed invention. That depends in significant
part on the construction of the term "biocompatible," a term
existing in each of the asserted claims. As noted above, the
district court construed "biocompatible" <span CLASS="page_no" data-cite="672 f 3d 1367" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1367" data-primary-citation="672 F.3d 1350">[*1367]</span> p-GlcNAc

to be limited to "polymers . . . with . . . no
<i>detectable biological reactivity</i> as determined by
biocompatibility tests." <i>Marine Polymer</i>,
[<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X18SNBG003?jcsearch=2008%20BL%2096692&amp;summary=yes#jcite">2008 BL 96692</a>], 2008 WL 1995454, at *10 (emphasis added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  One might at the outset be somewhat skeptical of this
construction because it was not proposed by either party and
was indeed contrary to the patentee's own proposed
construction. In the district court, Marine Polymer conceded
that "biocompatible p-GlcNAc" <span CLASS="page_no" data-cite="102 uspq 2d 1171" data-cite-type="ReporterOfDecisions" data-cite-pageno="1171" data-primary-citation="102 U.S.P.Q.2d 1161">[**1171]</span> could exhibit some biological
reactivity, arguing that the term should be interpreted to mean
"biomedically pure [p-GlcNAc] that reproducibly exhibits
<i>acceptably low levels of adverse bioreactivity</i>, as
determined by biocompatibility tests." Claim Construction
Order, <i>Marine Polymer Techs., Inc. v. HemCon, Inc.</i>,
<cite>No. 06-cv-100-JD</cite>, slip. op. at 2, [<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X18SNBG003?jcsearch=2008%20BL%2096692&amp;summary=yes#jcite">2008 BL 96692</a>], 2008 WL 1995454 (D.N.H. May
6, 2008) (emphasis added). Similarly, it argued in its
memorandum that its sample p-GlcNAc "showed acceptably low
adverse reactions" to each of the biocompatibility tests and
that this construction of "biocompatible p-GlcNAc" was "fully
supported" by the claims and specification. Memorandum in
Support of Plaintiffs Claim Construction, <i>Marine Polymer</i>
<i>Techs., Inc. v. HemCon, Inc.</i>, <cite>No. 06-cv-100-JD</cite>, at 7,
10-11 (D.N.H. Aug. 17, 2007), ECF No. 48-1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Whether or not Marine Polymer's own constructions are
binding, <a HREF="#fn101" name="fnref_fn101">[fn1]</a> the district court's construction is in fact
contrary to the specification and to the claims themselves. The
specification and claims are clear that "biocompatible"
p-GlcNAc encompasses polymers that exhibit some biological
reactivity. The specification "is the single best guide to the
meaning of a disputed term," <i>Phillips v. AWH Corp.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">415 F.3d 1303</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">1315</a> (Fed. Cir. 2005) (en banc), and may define a
term explicitly or by implication, <i>Irdeto Access, Inc. v.</i>
<i>EchoStar Satellite Corp.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XFPG3E?jcsearch=383%20f%203d%201295&amp;summary=yes#jcite">383 F.3d 1295</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XFPG3E?jcsearch=383%20f%203d%201295&amp;summary=yes#jcite">1300</a>
(Fed. Cir. 2004).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, the specification defines "biocompatible" in a manner
directly contrary to the district court's construction of "no
detectable biological reactivity." The specification first
discusses the concept of biocompatibility in the Detailed
Description of the Invention, stating that "[t]he p-GlcNAc of
the invention exhibits a high degree of biocompatibility."
&prime;<cite>245 Pat.</cite> col.10 11.49-50. The specification does not
provide at this point what constitutes an acceptably high
degree of biocompatibility, but it discloses that
"[b]iocompatability may be determined by a variety of
techniques, including, but not limited to such procedures as
the elution test, intramuscular implantation, or intracutaneous
<span CLASS="page_no" data-cite="2012 bl 67351 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> or systemic injection into animal subjects." <i><cite>Id</cite>.</i>
col.10 11.50-53. Each of these four "biocompatibility tests" is
later described in detail, including the particular materials,
methods, and conditions to properly perform each test on a
p-GlcNAc sample. The specification also discusses the results
of each of the four tests, and specifically defines what
constitutes "meet[ing]" the requirements of the particular
"biocompatibility test." <i>See <cite>id</cite>.</i> col.42 11.42-43.
Judge Lourie's opinion itself concedes that the specification
contemplates non-zero "passing" scores on the biocompatibility
tests. <i>See</i> Lourie Op. at 1358-59.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Notably, for each of the four tests, the specification does not
require that there be no biological reactivity but provides
that the test is satisfied where at least some reactivity is
present. For example, with respect to the elution test, the
specification states that "[t]he test article (i.e., p-GlcNAc)
<span CLASS="page_no" data-cite="672 f 3d 1368" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1368" data-primary-citation="672 F.3d 1350">[*1368]</span> 
meets the biocompatibility test if none of the cultures
treated with the test article show a <i>greater than mild</i>
<i>reactivity.</i>" &prime;<cite>245 Pat.</cite> col.42 11.41-43 (emphasis
added). Likewise, the specification explains that the
biocompatibility test using the other methods is met even if
the polymer exhibits some biological reactivity. <i>See</i>
<i><cite>id</cite>.</i> col.43 11.54-60, col.44 11.25-26, col.45 11.41-43.
Nowhere does the specification disavow or disclaim from the
scope of the claims polymers exhibiting these levels of
reactivity. If a polymer exhibiting some reactivity nonetheless
meets the specification's explicit requirements for
"biocompatibility," it cannot be that such polymer is not
"biocompatible" within the meaning of the claims. Thus, the
specification contemplates some level of reactivity that is
compatible with use in biomedical applications.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  If this description of biocompatibility in the specification
were not enough, the presence of six independent claims in the
original patent dictate that the "biocompatible" limitation
allow some exhibition of reactivity. Six dependent claims in
the original patent specifically required that the
"biocompatible" p-GlcNAc have an elution test score of either
one or two, which correspond to "slight" or "mild" reactivity
respectively and is directly inconsistent with a construction
requiring <i>no</i> reactivity. &prime;<cite>245 Pat.</cite> col.42
11.50-55. If "biocompatible" requires that there be no
reactivity, but these dependent claims require slight or mild
reactivity, they are nullified and become utterly meaningless.
Marine Polymer itself concedes that these six claims were
rendered meaningless by the district court's construction, and
that "the dependent claims requiring non-zero elution test
scores conflict with [the district court's] construction."
Appellee's Br. 28.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Where a particular construction of an independent claim would
nullify claims that depend from it, the doctrine of claim
differentiation creates a presumption that such a construction
is improper. <i>See Liebel-Flarsheim Co. v. Medrad, Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XE42MU?jcsearch=358%20f%203d%20898&amp;summary=yes#jcite">358 F.3d 898</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XE42MU?jcsearch=358%20f%203d%20898&amp;summary=yes#jcite">910</a> (Fed. Cir. 2004). We adopt a <span CLASS="page_no" data-cite="102 uspq 2d 1172" data-cite-type="ReporterOfDecisions" data-cite-pageno="1172" data-primary-citation="102 U.S.P.Q.2d 1161">[**1172]</span> construction of a
term which renders claims invalid or meaningless when it is <span CLASS="page_no" data-cite="2012 bl 67351 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> the
"<i>only</i> claim construction that is consistent with the
claim's language and the written description." <i>Rhine v.</i>
<i>Casio, Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X386A0?jcsearch=183%20f%203d%201342&amp;summary=yes#jcite">183 F.3d 1342</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X386A0?jcsearch=183%20f%203d%201342&amp;summary=yes#jcite">1345</a> (Fed. Cir. 1999) (emphasis
added). In other words, this presumption can be overcome only
where a contrary construction is "dictated" &mdash; i.e.,
compelled &mdash; by the written description or prosecution
history. <i>Seachange Int'l, Inc. v. C-COR, Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12GCDM003?jcsearch=413%20f%203d%201361&amp;summary=yes#jcite">413 F.3d 1361</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12GCDM003?jcsearch=413%20f%203d%201361&amp;summary=yes#jcite">1369</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12GCDM003?jcsearch=413%20f%203d%201361&amp;summary=yes#jcite">1370-72</a> (Fed. Cir. 2005) (holding that the
presumption established by claim differentiation was rebutted
because the written description "consistently" referred to the
claim term in a specific manner and arguments made during
prosecution amounted to a clear and unambiguous disclaimer of
claim scope). Here, there is an alternate claim construction,
one construing "biocompatible" to mean "little or no detectable
reactivity," which preserves the validity of these six
dependent claims. Nothing in the written description or
prosecution history overcomes the presumption by dictating or
compelling the conclusion that "biocompatible" is limited to
exhibiting "no detectable reactivity."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In supporting the district court's claim construction Judge
Lourie's opinion ignores or dismisses much of this compelling
evidence. The opinion suggests that the examiner's adoption of
the district court's construction supports the correctness of
that construction. Lourie Op. at 1359 n. 5. Quite the contrary.
During reexamination, Marine Polymer asked the examiner to
adopt the district court's construction of "biocompatible" in
evaluating whether the
<span CLASS="page_no" data-cite="672 f 3d 1369" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1369" data-primary-citation="672 F.3d 1350">[*1369]</span> 
claims were invalid as anticipated or obvious. The
examiner, however, rejected the district court's construction
and held that the "biocompatibility" limitation was not limited
to no reactivity but instead permitted "little or no detectable
reactivity." J.A. 39503. The examiner explained that this
definition "avoids creating the situation where claims 4, 5,
13, 14, 21 and 22 would be improper for failing to further
limit the claims from which they depend." J.A. 39504. Only
after these dependent claims were canceled to create
consistency with the district court's construction of
"biocompatible" did the examiner accept the district court's
construction. The examiner explained that "[w]ith the
cancellation of the claims which required that the elution test
scores were 1 or 2, the Examiner now agrees with the court's
definition of the term biocompatible." J.A. 39481.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Apart from its reliance on the examiner, Judge Lourie's opinion
rests its conclusion as to the correctness of the district
court's construction almost exclusively on the fact that there
are two instances in the entire specification where it refers
to the p-GlcNAc "of the invention." <i>See</i> Lourie Op.
at 1357-59. These two references, however, do not limit the scope
of the term "biocompatible." With respect to the first,
discussed above, the specification simply notes that the
"p-GlcNAc of the invention exhibits <i>a high degree of</i>
<i>biocompatibility.</i>" &prime;<cite>245 Pat</cite>. col.10 11.49-50
(emphasis added). There is no indication in the specification
that a high degree of biocompatibility is achieved only where
there, is <i>no</i> reactivity. <span CLASS="page_no" data-cite="2012 bl 67351 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> The passage suggests the
opposite. With respect to the second, the specification's
description of the p-GlcNAc "of the invention" was made in the
context of a specific example &mdash; one of eighteen in the
specification. Judge Lourie's opinion leaves out highly
pertinent language in quoting this portion of the
specification. The specification explicitly states that
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>[i]n this Example</i>, . . . the p-GlcNAc of the
  invention exhibits no detectable biological
  reactivity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><cite>Id</cite>.</i> col.41 11.66-67 (emphasis added). Judge Lourie's
opinion leaves out the "in this Example" language. This
reference does not suggest that the invention always "exhibits
no detectable biological reactivity"; rather, that it does so
"in this Example."<a HREF="#fn201" name="fnref_fn201">[fn2]</a> The mere fact that the p-GlcNAc tested
in this example in the specification showed no biological
reactivity, without more, cannot be sufficient to limit the
claim term "biocompatible" to polymers exhibiting no detectable
biological reactivity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The approach in Judge Lourie's opinion of interpreting a claim
limitation based solely on a single example from the
specification is an approach we have repeatedly rejected. See,
<i>e.g., Silicon Graphics, Inc. v. ATI Techs., Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1DC7PS003?jcsearch=607%20f%203d%20784&amp;summary=yes#jcite">607 F.3d 784</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1DC7PS003?jcsearch=607%20f%203d%20784&amp;summary=yes#jcite">792</a> (Fed. Cir. 2010) ("A construing court's reliance on
the specification must not go so far as to import limitations
into claims from examples or embodiments appearing only in a
patent's written description unless the specification makes
clear that the patentee intends for the claims and the
embodiments in the specification to be
<span CLASS="page_no" data-cite="672 f 3d 1370" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1370" data-primary-citation="672 F.3d 1350">[*1370]</span> 
strictly coextensive." (internal quotation marks omitted));
<i>Howmedica Osteonics <span CLASS="page_no" data-cite="102 uspq 2d 1173" data-cite-type="ReporterOfDecisions" data-cite-pageno="1173" data-primary-citation="102 U.S.P.Q.2d 1161">[**1173]</span> Corp. v. Wright Med. Tech., Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X19G87C003?jcsearch=540%20f%203d%201337&amp;summary=yes#jcite">540 F.3d 1337</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X19G87C003?jcsearch=540%20f%203d%201337&amp;summary=yes#jcite">1345</a> (Fed. Cir. 2008) ("[W]e have repeatedly held
that the fact that the specification describes only a single
embodiment, standing alone, is insufficient to limit otherwise
broad claim language."). We have "cautioned against limiting
the claimed invention to preferred embodiments or specific
examples in the specification." <i>Tex. Instruments, Inc. v.</i>
<i>U.S. Int'l Trade Comm'n</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XAFGCQ?jcsearch=805%20f%202d%201558&amp;summary=yes#jcite">805 F.2d 1558</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XAFGCQ?jcsearch=805%20f%202d%201558&amp;summary=yes#jcite">1563</a> (Fed. Cir.
1986). Indeed, the "[v]aried use of a disputed term in the
written description demonstrates the breadth of the term rather
than providing a limited definition." <i>Johnson Worldwide</i>
<i>Assocs., Inc. v. Zebco Corp.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X36IGJ?jcsearch=175%20f%203d%20985&amp;summary=yes#jcite">175 F.3d 985</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X36IGJ?jcsearch=175%20f%203d%20985&amp;summary=yes#jcite">991</a>
(Fed. Cir. 1999). This court has never, on such scant evidence as
exists here, found that a single embodiment disclosed in a
patent limited the scope of the claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Judge Lourie's new approach to claim construction would enable
patentees to eliminate questions of validity by narrowing
claims in accordance with a preferred embodiment or single
example, while also allowing alleged infringers to narrow
claims beyond their valid scope to avoid infringement. That
approach cannot be correct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   II
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under the correct claim construction, ignoring for a moment the
issue of intervening rights, HemCon at a minimum would be
entitled to a new trial on all issues related to the validity
of the original patent claims. The jury was specifically
instructed under the incorrect claim construction and answered
questions on the jury verdict form directly related to this
construction. J.A. Ill (asking <span CLASS="page_no" data-cite="2012 bl 67351 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[***19]</span> jury whether prior art discloses
"having no detectable biological reactivity as determined by
biocompatibility tests"). Moreover, after trial, the district
court denied HemCon's motion for JMOL and/or a new trial on
anticipation and obviousness because HemCon's expert's opinions
about the prior art "were based on the wrong definition of
biocompatibility," <i>Marine Polymer Techs., Inc. v. HemCon,</i>
<i>Inc.</i>, <cite>No. 06-cv-100-JD</cite>, [<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1Q6LCLPL5O2?jcsearch=2010%20BL%20172009&amp;summary=yes#jcite">2010 BL 172009</a>], 2010 WL 2902258, at *3
(D.N.H. July 21, 2010), and because the disputed prior art "did not
disclose p-GlcNAc with no detectable biological reactivity as
determined by biocompatibility tests," <i></i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1Q6LCLPL5O2?jcsearch=2010%20BL%20172009&amp;summary=yes#jcite">id. at *4</a>.
<i>See also </i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1Q6LCLPL5O2?jcsearch=2010%20DNH%20127&amp;summary=yes#jcite">id. at *8</a> ("[B]ecause none of the cited prior
art disclosed the properties of biocompatible p-GlcNAc, as
claimed by the &prime;245 patent, the evidence at trial did not
support findings for obviousness."). This reliance on this
incorrect claim construction alone warrants a new trial on
these issues, putting to one side the issue of intervening
rights. HemCon should at a minimum be permitted to defend
itself against claims of infringing the original patent by
attacking its validity under a proper claim construction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   III
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    A
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I turn then to the question of intervening rights. While the
judgment of the district court is affirmed by an equally
divided court, the district court rendered no judgment on the
question of intervening rights, and therefore there is nothing
to affirm in that respect. Nonetheless, I agree with Judge
Lourie that the effect of the equally divided affirmance is
that the district court's claim construction is binding on the
parties as if the district court's decision had never been
reviewed. <i>Durant <span CLASS="page_no" data-cite="672 f 3d 1371" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1371" data-primary-citation="672 F.3d 1350">[*1371]</span> v. Essex Co., <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM03SN?jcsearch=74%20U.S.%20107&amp;summary=yes#jcite">7 Wall. 107</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM03SN?jcsearch=74%20us%20107&amp;summary=yes#jcite">74 U.S. 107</a>,</i>

<i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM03SN?jcsearch=113&amp;summary=yes#jcite">113</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM03SN?jcsearch=19%20l%20ed%20154&amp;summary=yes#jcite">19 L.Ed. 154</a> (1868) (holding that an affirmance by an</i>
<i>equally divided court "is as conclusive and binding in every</i>
<i>respect upon the parties as if rendered upon the concurrence of</i>
<i>all the judges upon every question involved in the case</i>").<a HREF="#fn301" name="fnref_fn301">[fn3]</a>
The result is that there can be no intervening rights.
In other words, under the district court's incorrect claim
construction, now binding on the parties as a result of the
affirmance of the district court's judgment, the original and
reexamined claims are identical in scope, and there is thus no
issue of intervening rights and no need for the majority to offer
"an alternative ground for decision." Remarkably, the majority
goes on to legislate an interpretation of the intervening rights
statute. This is, to say the least, an unusual approach. It is
particularly odd because the majority thinks that the issue is
not properly before us (even if the district court's claim
construction was wrong) because the intervening rights issue
was not addressed by the district court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In my view the issue is properly before us. Here, while the
district court entered judgment on September 22, 2010, and
HemCon filed its Notice of Appeal to this court on September
24, 2010, the examiner did not issue the Notice of Intent to
Issue an Ex Parte Reexamination Certificate until November 3,
2010, well after the appeal to this court. The majority offers
no reasons why we should not consider the changes to a patent
<span CLASS="page_no" data-cite="2012 bl 67351 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[***20]</span> effected by reexamination. Just as we are obligated to take
account of intervening changes in law that affect an appeal,
<i>see Bradley v. Sch. Bd. of City of Richmond</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X2N6FU?jcsearch=416%20us%20696&amp;summary=yes#jcite">416 U.S. 696</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X2N6FU?jcsearch=416%20us%20696&amp;summary=yes#jcite">714-15</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X2N6FU?jcsearch=94%20supreme%20court%202006&amp;summary=yes#jcite">94 S.Ct. 2006</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X2N6FU?jcsearch=40%20l%20ed%202d%20476&amp;summary=yes#jcite">40 L.Ed.2d 476</a> (1974);
<i><span CLASS="page_no" data-cite="102 uspq 2d 1174" data-cite-type="ReporterOfDecisions" data-cite-pageno="1174" data-primary-citation="102 U.S.P.Q.2d 1161">[**1174]</span> Vandenbark v. Owens-Illinois Glass Co.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C067?jcsearch=311%20us%20538&amp;summary=yes#jcite">311 U.S. 538</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C067?jcsearch=311%20us%20538&amp;summary=yes#jcite">542-43</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C067?jcsearch=61%20supreme%20court%20347&amp;summary=yes#jcite">61 S.Ct. 347</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C067?jcsearch=85%20l%20ed%20327&amp;summary=yes#jcite">85 L.Ed. 327</a> (1941), we are obligated to
take account of changes to a patent that occur during the
pendency of a case on appeal, <i>see Watts, Watts &amp; Co. v.</i>
<i>Unione Austriaca Di Navigazione</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BREI?jcsearch=248%20us%209&amp;summary=yes#jcite">248 U.S. 9</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BREI?jcsearch=248%20us%209&amp;summary=yes#jcite">21</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BREI?jcsearch=39%20supreme%20court%201&amp;summary=yes#jcite">39 S.Ct. 1</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BREI?jcsearch=63%20l%20ed%20100&amp;summary=yes#jcite">63 L.Ed. 100</a> (1918) (holding that "court[s] must consider
the changes in fact and in law which have supervened since the
decree was entered below"). Ample authority, uncontradicted by
the majority, supports the original panel's approach of
addressing the issue of intervening rights, <a HREF="#fn401" name="fnref_fn401">[fn4]</a> and the
majority has offered no support for its position that a court
cannot take judicial notice of changes that occur while the
case is pending on appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority, though believing that the issue is not properly
before us and that the issue is resolved by the district
court's claim construction, excuses its discussion of
intervening rights by the fact that the original panel opinion
"dealt extensively
<span CLASS="page_no" data-cite="672 f 3d 1372" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1372" data-primary-citation="672 F.3d 1350">[*1372]</span> 
with this issue," and thus this court must "decide the case
as we find it and clarify the law." Maj. Op. at 1365. But the
panel opinion has been vacated, and, if the issue is not in
fact properly before us, and is unnecessary in any event, there
is no possible reason for addressing it. If this were not
enough, the Supreme Court has repeatedly counseled against
writing opinions where a judgment has been affirmed by an
equally divided court, <a HREF="#fn501" name="fnref_fn501">[fn5]</a> a practice that the majority here
disregards.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    B
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On the merits of the intervening rights issue, the majority is
incorrect as a matter statutory interpretation. Section 307(b)
provides:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Any proposed <i>amended or new claim</i> determined
  to be patentable and incorporated into a patent
  following a reexamination proceeding <i>will have the</i>
  <i>same effect as that specified in <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">section 252</a> of this</i>
  <i>title</i> for reissued patents on the right of any
  person who made, purchased, or used within the United
  States, or imported into the United States, anything
  patented by such proposed amended or new claim, or who
  made substantial preparation for the same, prior to
  issuance of a certificate under the provisions of
  <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(a)&amp;summary=yes#jcite">subsection (a)</a> of this section.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">35 U.S.C. &sect; 307</a>(b) (emphasis added). <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">Section 307(b)</a> thus
specifically incorporates the intervening rights provisions of
reissued patents found in <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">section 252</a>. Congress was explicit
that <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">section 307(b)</a> should be interpreted to be identical in
scope to <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">section 252</a>:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Subsection <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">307(b)</a> provides intervening rights</i>
  <i>similar to those provided by patent law <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">section 252</a></i>
  <i>with respect to reissued patents.</i> Thus, a person
  practicing a patented invention would not be
  considered an infringer for the period between
  issuance of an invalid patent and its conversion
  through reexamination to a valid patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
H.R. Rep. No. 96-1307(1), at 8 (1980), 1980 U.S.C.C.A.N. 6460,
6467 (emphasis added).<a HREF="#fn601" name="fnref_fn601">[fn6]</a> Thus, the "amended or new" language
<span CLASS="page_no" data-cite="672 f 3d 1373" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1373" data-primary-citation="672 F.3d 1350">[*1373]</span> 
in <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">section 307(b)</a> was clearly intended to have the same
meaning as "substantially <span CLASS="page_no" data-cite="102 uspq 2d 1175" data-cite-type="ReporterOfDecisions" data-cite-pageno="1175" data-primary-citation="102 U.S.P.Q.2d 1161">[**1175]</span> identical" in <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">section 252</a>. The focus
is on whether the old and new claims are "substantially
identical." <span CLASS="page_no" data-cite="2012 bl 67351 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[***21]</span> In another case analyzing intervening rights
related to a reexamined patent, this court explained:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A patentee of a reexamined patent is entitled to
  infringement damages, <i>inter alia</i>, for the
  period between the date of issuance of the original
  claims and the date of issuance of the reexamined
  claims if the original and reexamined claims are
  "identical." <i>Reexamined claims are "identical" to</i>
  <i>their original counterparts if they are "without</i>
  <i>substantive change.</i>" Furthermore, in determining
  whether substantive changes have been made, we must
  discern whether the <i>scope</i> of the claims are identical,
  <i>not merely whether different words are used.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Laitram Corp. v. NEC Corp.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X40T8K?jcsearch=163%20f%203d%201342&amp;summary=yes#jcite">163 F.3d 1342</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X40T8K?jcsearch=163%20f%203d%201342&amp;summary=yes#jcite">1346</a>
(Fed. Cir. 1998) (internal citations omitted) (first and third
emphases added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, the original and new claims are not "substantially
identical." During reexamination the patentee agreed, by both
argument and by amending the claims to cancel six dependent
claims, that the term "biocompatible" should be construed to
mean "no detectable biological reactivity." In doing so, as
discussed above, the patentee adopted a construction that was
different than the correct construction of the original claims,
namely that "biocompatible" meant, inter alia, "little or no
detectable reactivity." The effect was to narrow the claims and
protect them from a finding of invalidity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the majority recognizes, <i>see</i> Maj. Op. at 1363-64,
it is well established that statements during prosecution or
reexamination of a patent, as well as additions or deletions of
claims to overcome rejections, can change the meaning of a
claim term that would ordinarily be construed otherwise.
<i>See Am. Piledriving Equip., Inc. v. Geoquip, Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1F5446003?jcsearch=637%20f%203d%201324&amp;summary=yes#jcite">637 F.3d 1324</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1F5446003?jcsearch=637%20f%203d%201324&amp;summary=yes#jcite">1336</a> (Fed. Cir. 2011); <i>CIAS, Inc. v. Alliance</i>
<i>Gaming Corp.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X17NN9G003?jcsearch=504%20f%203d%201356&amp;summary=yes#jcite">504 F.3d 1356</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X17NN9G003?jcsearch=504%20f%203d%201356&amp;summary=yes#jcite">1362-63</a> (Fed. Cir. 2007);
<i>C.R. Bard, Inc. v. U.S. Surgical Corp.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XFPDCG?jcsearch=388%20f%203d%20858&amp;summary=yes#jcite">388 F.3d 858</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XFPDCG?jcsearch=388%20f%203d%20858&amp;summary=yes#jcite">867-69</a> (Fed. Cir. 2004); <i>Cole v. Kimberly-Clark Corp.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X350N7?jcsearch=102%20f%203d%20524&amp;summary=yes#jcite">102 F.3d 524</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X350N7?jcsearch=102%20f%203d%20524&amp;summary=yes#jcite">532</a> (Fed. Cir. 1996). Here, although identical in
language, the claims of the patent after reexamination were not
identical in scope for purposes of intervening rights because
they were "substantively changed" during reexamination.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority makes much of the difference in language between
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">sections 307(b)</a> and <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">252</a>, pointing out that <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.307(b)&amp;summary=yes#jcite">section 307(b)</a>
includes the language "amended or new claims." The majority
limits an "amended" claim under <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">section 307(b)</a> to a situation
in which the claim language itself is changed. This
interpretation ignores the statute's language, its purpose, and
the history of intervening rights.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because the statute does not define "amended," this term is
"assumed to bear [its] `ordinary, contemporary, common
meaning.'" <i>Walters v. Metro. Educ. Enters., Inc.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CCS7?jcsearch=519%20us%20202&amp;summary=yes#jcite">519 U.S. 202</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CCS7?jcsearch=519%20us%20202&amp;summary=yes#jcite">207</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CCS7?jcsearch=117%20supreme%20court%20660&amp;summary=yes#jcite">117 S.Ct. 660</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CCS7?jcsearch=136%20l%20ed%202d%20644&amp;summary=yes#jcite">136 L.Ed.2d 644</a> (1997) (quoting
<i>Pioneer Inv. Servs. Co. v. Brunswick Assocs. Ltd.</i>
<i>P'ship</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CC8E?jcsearch=507%20us%20380&amp;summary=yes#jcite">507 U.S. 380</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CC8E?jcsearch=507%20us%20380&amp;summary=yes#jcite">388</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CC8E?jcsearch=113%20supreme%20court%201489&amp;summary=yes#jcite">113 S.Ct. 1489</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CC8E?jcsearch=123%20l%20ed%202d%2074&amp;summary=yes#jcite">123 L.Ed.2d 74</a>
(1993)). While "amend" may often connote an actual change in
language, <a HREF="#fn701" name="fnref_fn701">[fn7]</a> that is not the only meaning of the term
"amend."
<span CLASS="page_no" data-cite="672 f 3d 1374" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1374" data-primary-citation="672 F.3d 1350">[*1374]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There are a number of cases decided in similar contexts that
make clear that a written document can be "amended" without a
language change. For example, <i>National Knitwear</i>
<i>Manufacturers Ass'n v. Consumer Product Safety Commission</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3PAOD?jcsearch=666%20f%202d%2081&amp;summary=yes#jcite">666 F.2d 81</a> (4th Cir. 1981), is quite similar to this case. In
<i>National Knitwear</i>, the Flammable Fabrics Act required
<span CLASS="page_no" data-cite="2012 bl 67351 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[***22]</span> the Consumer Product Safety Commission to comply with specific
procedures, in addition to those under the Administrative
Procedure Act, in order to issue "a <i>new or amended</i>
flammability standard." <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEHFOC003?jcsearch=15%20U.S.C.%201193&amp;summary=yes#jcite">15 U.S.C. &sect; 1193</a> (1976) (emphasis
added). The flammability standards for children's sleepwear
included a definition of "[c]hildren's [s]leepwear" that
specifically excluded "underwear." <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XMIA58003?jcsearch=16%20C.F.R.%201615.1(a)&amp;summary=yes#jcite">16 C.F.R. &sect; 1615.1</a>(a)
(1980). Thereafter, the Commission issued a statement, without
complying with the Act, indicating that "despite a garment's
being labeled as underwear and unsuitable for sleep-wear, the
Commission may bring an enforcement action if it believes that
the garment is intended to be worn primarily for sleeping or
that it has been promoted as sleepwear." <i>Nat'l</i>
<i>Knitwear</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3PAOD?jcsearch=666%20f%202d%2081&amp;summary=yes#jcite">666 F.2d at 83</a>. The Fourth Circuit held that the
Act had been violated because, although the text of the
flammability standards had not changed, "the Commission ha[d]
in effect <i>amended</i> the standard despite the express
exclusion of underwear from the definition of sleepwear."
<i></i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3PAOD?jcsearch=666%20F.2d%20at%2084&amp;summary=yes#jcite">Id. at 84</a> (emphasis added). Just as the standard in
<i>National Knitwear</i> was "amended" by an agency
statement, so here the claims have been "amended" by a
disclaimer in the reexamination.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In many other contexts the word "amend" has been interpreted as
not requiring an explicit language change. In the context of
the <span CLASS="page_no" data-cite="102 uspq 2d 1176" data-cite-type="ReporterOfDecisions" data-cite-pageno="1176" data-primary-citation="102 U.S.P.Q.2d 1161">[**1176]</span> Administrative Procedure Act, amending an interpretive
rule can be considered "amending . . . a rule" under <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEGOVC003?jcsearch=5%20U.S.C.%20%20551(5)&amp;summary=yes#jcite">section 551(5)</a>,
thus requiring notice and comment, even if there is no
alteration in the language of the rule itself. <i>United</i>
<i>States v. Magnesium Corp. of Am.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1E2MNG003?jcsearch=616%20f%203d%201129&amp;summary=yes#jcite">616 F.3d 1129</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1E2MNG003?jcsearch=616%20f%203d%201129&amp;summary=yes#jcite">1139</a>
(10th Cir. 2010). As the Tenth Circuit has held, "if an agency
amends its interpretation of a rule, it is effectively amending
the rule itself." <i><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1E2MNG003?jcsearch=616%20F.3d%201129&amp;summary=yes#jcite">Id</a>.</i> (internal quotation marks
omitted); <i>see also Jerri's Ceramic Arts, Inc. v. Consumer</i>
<i>Prod. Safety Comm'n</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XAFKSF?jcsearch=874%20f%202d%20205&amp;summary=yes#jcite">874 F.2d 205</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XAFKSF?jcsearch=874%20f%202d%20205&amp;summary=yes#jcite">206</a> (4th Cir. 1989)
(finding that an agency "interpretation" was in fact a
substantive "amendment" to the Small Parts Rule, and thus the
agency violated the APA). Legal instruments can often be
constructively or effectively amended without changing literal
text. <i>See, e.g., Chamberlain Group, Inc. v. Skylink Techs.,</i>
<i>Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XFPGGM?jcsearch=381%20f%203d%201178&amp;summary=yes#jcite">381 F.3d 1178</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XFPGGM?jcsearch=381%20f%203d%201178&amp;summary=yes#jcite">1189</a> (Fed. Cir. 2004) ("For the purpose
of determining Federal Circuit jurisdiction, we do not
differentiate between actual and constructive amendments [to
the complaint]."); <i>see also, e.g., Battoni v. IBEW Local</i>
<i>Union No. 102 Emp. Pension Plan</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1CGBDQ003?jcsearch=594%20f%203d%20230&amp;summary=yes#jcite">594 F.3d 230</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1CGBDQ003?jcsearch=594%20f%203d%20230&amp;summary=yes#jcite">235</a> (3d
Cir. 2010) (constructive amendment to pension plan); <i>United</i>
<i>States v. Starr</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X194AMS003?jcsearch=533%20f%203d%20985&amp;summary=yes#jcite">533 F.3d 985</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X194AMS003?jcsearch=533%20f%203d%20985&amp;summary=yes#jcite">997</a> (8th Cir. 2008)
(constructive amendment to a criminal indictment); <i>S. Colo.</i>
<i>MRI, Ltd. v. Med-Alliance, Inc.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X37VIV?jcsearch=166%20f%203d%201094&amp;summary=yes#jcite">166 F.3d 1094</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X37VIV?jcsearch=166%20f%203d%201094&amp;summary=yes#jcite">1099</a> (10th
Cir. 1999) ("By expressing an intent to be bound on July 7,
1993, the parties implicitly . . . <i>amended</i> any prior
[written] agreement that an asset purchase document was
necessary to complete the contract."). A statute may also be
amended without a change in language. <i>See United States ex</i>
<i>rel. Palmer v. Lapp</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XFL3GV?jcsearch=244%20f%20377&amp;summary=yes#jcite">244 F. 377</a> (6th Cir. 1917) (finding
that an act independent
<span CLASS="page_no" data-cite="672 f 3d 1375" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1375" data-primary-citation="672 F.3d 1350">[*1375]</span> 
and original in form, which in effect added a provision to
an existing statute, was an "amendment" within the meaning of a
reference in another act to that statute "and amendments
thereto"). In general, an act that changes the substance of a
statute <span CLASS="page_no" data-cite="2012 bl 67351 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[***23]</span> without changing its language is commonly referred to
as an "amendment by implication." <i>See United States v.</i>
<i>Welden</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C5VJ?jcsearch=377%20us%2095&amp;summary=yes#jcite">377 U.S. 95</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C5VJ?jcsearch=377%20us%2095&amp;summary=yes#jcite">103</a> n. 12, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C5VJ?jcsearch=84%20supreme%20court%201082&amp;summary=yes#jcite">84 S.Ct. 1082</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C5VJ?jcsearch=12%20l%20ed%202d%20152&amp;summary=yes#jcite">12 L.Ed.2d 152</a> (1964); <i>Agri Processor Co. v. NLRB</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XK5GD8N?jcsearch=514%20f%203d%201&amp;summary=yes#jcite">514 F.3d 1</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XK5GD8N?jcsearch=514%20f%203d%201&amp;summary=yes#jcite">4</a>
(D.C. Cir. 2008). Thus, the plain language of the term "amended"
does not require a language change.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The history of intervening rights provisions themselves compel
an interpretation of "amended" that does not require a change
in the language of the claims. The doctrine of intervening
rights with respect to reissued patents existed as a judicial
construct since the 1800s. <i>See generally</i> P.J.
Federico, <i>Intervening Rights in Patent Reissues</i>,
30 Geo. Wash. L. Rev. 603 (1961). <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.%20252&amp;summary=yes#jcite">Section 252</a> in the Patent Act of
1952 substantially adopted and clarified the doctrine of
intervening rights as it had been interpreted and developed by
the courts. <i>See</i> H.R. Rep. No. 82-1923, at 8 (1952);
<i>see also</i> Federico, <i><cite>supra</cite></i>, at 629-30. Courts
for years have understood that the specification and the claims
together act to define an invention. The Supreme Court
recognized that the scope of patents could be changed by an
amendment to the specification where there is no formal
amendment to the claim. <i>See, e.g., Russell v. Dodge</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1I0B?jcsearch=93%20us%20460&amp;summary=yes#jcite">93 U.S. 460</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1I0B?jcsearch=93%20us%20460&amp;summary=yes#jcite">463</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1I0B?jcsearch=23%20l%20ed%20973&amp;summary=yes#jcite">23 L.Ed. 973</a> (1876) (noting that a
specification might "be substantially changed, either by the
addition of new matter or the omission of important
particulars, so as to enlarge the scope of the invention as
originally claimed").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court made clear that a change in the specification
broadening the scope of the patent, just as a change to claim
language, could lead to intervening rights. For example, in
<i>Battin v. Taggert</i> the Court noted that
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  [w]hether the defect be <i>in the specifications</i>
  or in the claim . . ., the patentee may surrender his
  patent, and, by an amended specification or claim,
  cure the defect. . . . But <i>where the</i>
  <i>specification</i> or claim <i>is made so vaguely as</i>
  <i>to be inoperative and invalid</i>, yet an amendment
  may give to it validity, and protect the rights of the
  patentee against all subsequent infringements.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1GVR?jcsearch=58%20us%2074&amp;summary=yes#jcite">58 U.S. 74</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1GVR?jcsearch=58%20us%2074&amp;summary=yes#jcite">83</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1GVR?jcsearch=17%20How.%2074&amp;summary=yes#jcite">17 How. 74</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XM1GVR?jcsearch=15%20l%20ed%2037&amp;summary=yes#jcite">15 L.Ed. 37</a> (1854) (emphasis
added). Similarly, in a case where a patentee had amended the
specification during reissue by, inter alia, inserting an
additional figure, one court held that "[t]he law does not
permit such an enlargement of the original specifications as
will interfere with other inventors who have acquired
intervening rights." <i>Ficklen v. Baker</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XN0Q77QNB5G0?jcsearch=47%20appeals%20court%20dc%20587&amp;summary=yes#jcite">47 App. D.C. 587</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XN0Q77QNB5G0?jcsearch=47%20appeals%20court%20dc%20587&amp;summary=yes#jcite">596</a> (D.C. Cir. 1918) (quoting <i>Manly v. Williams</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XGBL0O?jcsearch=37%20appeals%20court%20dc%20194&amp;summary=yes#jcite">37 App. D.C. 194</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XGBL0O?jcsearch=37%20appeals%20court%20dc%20194&amp;summary=yes#jcite">201</a> (D.C. Cir. 1911)). Thus, prior to Congress
enacting the intervening rights provisions of <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.252&amp;summary=yes#jcite">section 252</a>,
courts understood that not having a change in claim language
was not indispensible to creating intervening rights, and that
a change in the specification could also lead to intervening
rights. Contrary to the majority's assertion, I do not claim
that these cases directly control this case. They do, however,
make clear that the Supreme Court, in developing the doctrine
of intervening rights, concluded that the scope of the claims
could change without formal amendments and still require the
recognition of intervening rights. There is no indication in
the legislative history of <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.252&amp;summary=yes#jcite">section 252</a> that Congress intended
to overrule the courts' <span CLASS="page_no" data-cite="2012 bl 67351 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[***24]</span> understanding on this
<span CLASS="page_no" data-cite="672 f 3d 1376" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1376" data-primary-citation="672 F.3d 1350">[*1376]</span> 
point. <i>See</i> H.R. Rep. No. 82-1923. As noted,
<span CLASS="page_no" data-cite="102 uspq 2d 1177" data-cite-type="ReporterOfDecisions" data-cite-pageno="1177" data-primary-citation="102 U.S.P.Q.2d 1161">[**1177]</span> <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307&amp;summary=yes#jcite">section 307</a>, added in 1980, was explicitly designed to provide
"similar" intervening rights as those provided in <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.252&amp;summary=yes#jcite">section 252</a>.
<i><cite>Id</cite>.</i> If a change in the language of the specification
could result in an "amended" claim, it is difficult to see why
a change in claim scope achieved by argument cannot also result
in an amended claim.<a HREF="#fn801" name="fnref_fn801">[fn8]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Most important, we must interpret "amended" to effectuate the
intent of Congress in enacting the intervening rights
provisions of the reexamination statutes. <i>See Reves v.</i>
<i>Ernst &amp; Young</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X2NVC8?jcsearch=494%20us%2056&amp;summary=yes#jcite">494 U.S. 56</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X2NVC8?jcsearch=494%20us%2056&amp;summary=yes#jcite">62-63</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X2NVC8?jcsearch=110%20supreme%20court%20945&amp;summary=yes#jcite">110 S.Ct. 945</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X2NVC8?jcsearch=108%20l%20ed%202d%2047&amp;summary=yes#jcite">108 L.Ed.2d 47</a> (1990) ("Thus, the phrase `any note' should not be
interpreted to mean literally `any note,' but must be
understood against the backdrop of what Congress was attempting
to accomplish in enacting the Securities Acts."). If "amended"
only refers to changes in the actual language of the claims,
the purpose of intervening rights will be plainly and directly
thwarted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is initially important to understand that the majority
agrees that claim scope can be changed by arguments made by the
patentee during reexamination.<a HREF="#fn901" name="fnref_fn901">[fn9]</a> In other words, the
fundamental assumption of the majority is that even where
argument in the reexamination proceeding changes the scope of
the claim, there are no intervening rights unless there is a
formal amendment to the claim. What the majority does not tell
us &mdash; in large part because it chooses to address this
issue in dictum without applying the rule to this case &mdash;
is whether, when there is a change in claim scope without
formal amendment, (1) the changed claim scope is retroactive to
validate the patent as of its original issue date, or (2) the
accused infringer can still challenge the validity of the
patent during the pre-examination period.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Neither of these alternatives makes sense, and each directly
contradicts the purpose of the statute, thus demonstrating
<span CLASS="page_no" data-cite="672 f 3d 1377" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1377" data-primary-citation="672 F.3d 1350">[*1377]</span> 
the error in the majority's statutory interpretation. The
first alternative &mdash; retroactively validating the original
patent by changing its scope &mdash; leads to an unfair and
absurd result. As recognized by the majority, this is precisely
the unfairness that led to the development of the doctrine of
intervening rights in the first place. <i>See</i> Maj. Op.
at 1361 ("The doctrine of intervening rights first developed as
courts recognized that permitting substantive changes to the
scope of patent claims through post-issuance procedures left
`the door . . . open for <i>gross injustice</i>' where a
third party, having already begun to make, use, or sell a given
article, finds its previously lawful activities rendered newly
infringing under a modified patent." (quoting <i>Sontag Chain</i>
<i>Stores Co. v. Nat'l Nut Co.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=310%20us%20281&amp;summary=yes#jcite">310 U.S. 281</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=310%20us%20281&amp;summary=yes#jcite">293-95</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=60%20supreme%20court%20961&amp;summary=yes#jcite">60 S.Ct. 961</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C04K?jcsearch=84%20l%20ed%201204&amp;summary=yes#jcite">84 L.Ed. 1204</a> (1940) (emphasis added))). The
intervening rights provisions make clear that the reexamined
and changed claims are valid only for the future after
reexamination. As noted in <i>Bloom Engineering Co. v. North</i>
<i>American Manufacturing Co.</i>,
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Sections <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20%20307&amp;summary=yes#jcite">307</a> and <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.252&amp;summary=yes#jcite">252</a> shield those who deem an
  adversely held patent to be invalid; if the patentee
  later cures the infirmity by reissue or reexamination,
  the making of substantive changes in the <span CLASS="page_no" data-cite="2012 bl 67351 p 25" data-cite-type="Bloomberg" data-cite-pageno="25" data-primary-citation="">[***25]</span> claims is
  treated as an irrebuttable presumption that the
  original claims were materially flawed. <i>Thus the</i>
  <i>statute relieves those who may have infringed the</i>
  <i>original claims from liability during the period</i>
  <i>before the claims are validated.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X54N8U?jcsearch=129%20f%203d%201247&amp;summary=yes#jcite">129 F.3d 1247</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X54N8U?jcsearch=129%20f%203d%201247&amp;summary=yes#jcite">1249</a> (Fed. Cir. 1997) (emphasis added). The second
alternative &mdash; creating a judicial version of intervening
<span CLASS="page_no" data-cite="102 uspq 2d 1178" data-cite-type="ReporterOfDecisions" data-cite-pageno="1178" data-primary-citation="102 U.S.P.Q.2d 1161">[**1178]</span> rights &mdash; is even more directly contrary to the statute.
Congress having considered the doctrine of intervening rights
cannot have intended that the judiciary would develop a poor
man's version of the doctrine to account for the statute's
inadequate coverage. This strongly suggests that the statute
should cover amendments by disclaimer.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Tellingly, the amici who support the court's interpretation of
the statute recognize that formal amendments to claim language
during the course of reexamination are unusual. <i>See</i>
Amicus Br. of Soverain et al. at 10. Telling too they admit
that formal amendments are now, and will be, avoided for the
very purpose of avoiding the creation of intervening rights.
<i></i><cite>Id. at 4</cite> (arguing that patent owners often "follow a
course of not seeking to amend their asserted claims, with the
settled understanding that if they could avoid claim
amendments, they could also avoid intervening rights"). In
other words, applicants will amend claims by argument rather
than formal methods for the very purpose of avoiding
intervening rights.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This very problem has led numerous amici to oppose the
majority's mechanical construction of the term "amend" and to
recognize that the majority's interpretation of intervening
rights will create the very opportunities for mischief and
"foster gamesmanship" that the statute was designed to avoid.
Amicus Br. of Geico et al. at 9-10 ("[U]nder such a rule,
patentees will be reluctant to change the words of their claims
during reexamination or reissue and, instead, badger examiners
with arguments changing the meaning of the words in the
claims."); Amicus Br. of Hewlett-Packard Co. et al. at 11
("Appellee's reading of the statute to exclude claims narrowed
through disclaimer would lead to absurd results and discourage
formal claim amendments in favor of prosecution history
maneuvering."). The majority's construction of the statute
defeats the public notice function of the patent system
<span CLASS="page_no" data-cite="672 f 3d 1378" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1378" data-primary-citation="672 F.3d 1350">[*1378]</span> 
by encouraging patentees to define the scope of the
invention outside of the claims themselves, thus not apprising
accused infringers of what is available to them.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Allowing patent owners to avoid creating intervening rights by
amending claims by argument is an abuse of the reexamination
process and undermines the purpose of intervening rights.
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">Section 307(b)</a> cannot be construed to sanction such abuses.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To be sure, not every argument during reexamination should give
rise to intervening rights, but intervening rights should be
available where an argument during reexamination rises to the
level of a clear and unambiguous disclaimer or disavowal of the
original, correct claim construction. Here, Marine Polymer
clearly and unambiguously disclaimed <span CLASS="page_no" data-cite="2012 bl 67351 p 26" data-cite-type="Bloomberg" data-cite-pageno="26" data-primary-citation="">[***26]</span> the scope of its claim by
effectively becoming its own lexicographer and presenting a
specific, limiting definition of the term
"biocompatible."<a HREF="#fn1001" name="fnref_fn1001">[fn10]</a> I respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn101" name="fn101">[fn1]</a></span> <i>See Key Pharms. v. Hereon Labs. Corp.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XACCUE?jcsearch=161%20f%203d%20709&amp;summary=yes#jcite">161 F.3d 709</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XACCUE?jcsearch=161%20f%203d%20709&amp;summary=yes#jcite">715</a> (Fed. Cir. 1998) ("Ordinarily, doctrines of estoppel,
waiver, invited error, or the like would prohibit a party from
asserting as `error' a position that it had advocated at the
trial.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn201" name="fn201">[fn2]</a></span> I also note that the p-GlcNAc tested in this example was
produced through the "Mechanical Force" method described in the
specification. &prime;245 Pat. col.42 11.15-17. The
specification, however, also discloses other methods for
producing p-GlcNAc with different "characteristics and
advantageous features." <i>See id.</i> col. 13 11.46-67.
There is no indication in the specification that p-GlcNAc
produced pursuant to a different method would similarly not
exhibit any biological reactivity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn301" name="fn301">[fn3]</a></span> The claim construction is, of course, not precedential.
<i>See, e.g., Neil v. Biggers</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C892?jcsearch=409%20us%20188&amp;summary=yes#jcite">409 U.S. 188</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C892?jcsearch=409%20us%20188&amp;summary=yes#jcite">192</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C892?jcsearch=93%20supreme%20court%20375&amp;summary=yes#jcite">93 S.Ct. 375</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C892?jcsearch=34%20l%20ed%202d%20401&amp;summary=yes#jcite">34 L.Ed.2d 401</a> (1972).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn401" name="fn401">[fn4]</a></span> <i>See Hawkes v. Internal Revenue Serv.</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3N29N?jcsearch=467%20f%202d%20787&amp;summary=yes#jcite">467 F.2d 787</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X3N29N?jcsearch=467%20f%202d%20787&amp;summary=yes#jcite">793</a> (6th Cir. 1972) ("This Court is obligated to take
notice of changes in fact or law occurring during the; pendency
of a case on appeal which would make a lower court's decision,
though perhaps correct at the time of its entry, operate to
deny litigants substantial justice."); <i>see also L.E.A.</i>
<i>Dynatech Inc. v. Allina</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X4NB07?jcsearch=49%20f%203d%201527&amp;summary=yes#jcite">49 F.3d 1527</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X4NB07?jcsearch=49%20f%203d%201527&amp;summary=yes#jcite">1531</a> (Fed. Cir.
1995) (explaining that an "appellate court will consider an
issue not presented below" if it, inter alia, "involves a pure
question of law and refusal to consider it would result" in an
injustice or "the appellant had no opportunity to raise the
objection at the district court level"); <i>Borlem</i>
<i>S.A.-Empreedimentos Industriais v. United States</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X30K7C?jcsearch=913%20f%202d%20933&amp;summary=yes#jcite">913 F.2d 933</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X30K7C?jcsearch=913%20f%202d%20933&amp;summary=yes#jcite">939</a> (Fed. Cir. 1990) ("[A] reviewing court is not precluded
. . . from considering events which have occurred between the
date of an agency (or trial court) decision and the date of
decision on appeal.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn501" name="fn501">[fn5]</a></span> <i>Ohio ex rel. Eaton v. Price</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C4NO?jcsearch=364%20us%20263&amp;summary=yes#jcite">364 U.S. 263</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C4NO?jcsearch=364%20us%20263&amp;summary=yes#jcite">264</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C4NO?jcsearch=80%20supreme%20court%201463&amp;summary=yes#jcite">80 S.Ct. 1463</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5C4NO?jcsearch=4%20l%20ed%202d%201708&amp;summary=yes#jcite">4 L.Ed.2d 1708</a> (1960) (explaining that where a
judgment is affirmed by an equally divided court, "the usual
practice is not to express any opinion, for such an expression
is unnecessary where nothing is settled"); <i>see also Etting</i>
<i>v. Bank of United States</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BRJ8?jcsearch=24%20us%2059&amp;summary=yes#jcite">24 U.S. 59</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BRJ8?jcsearch=24%20us%2059&amp;summary=yes#jcite">77-78</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BRJ8?jcsearch=11%20Wheat.%2059&amp;summary=yes#jcite">11 Wheat. 59</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BRJ8?jcsearch=6%20l%20ed%20419&amp;summary=yes#jcite">6 L.Ed. 419</a> (1826); <i>The Antelope</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BQD7?jcsearch=23%20us%2066&amp;summary=yes#jcite">23 U.S. 66</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BQD7?jcsearch=23%20us%2066&amp;summary=yes#jcite">126</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BQD7?jcsearch=10%20Wheat.%2066&amp;summary=yes#jcite">10 Wheat. 66</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BQD7?jcsearch=6%20l%20ed%20268&amp;summary=yes#jcite">6 L.Ed. 268</a> (1825).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn601" name="fn601">[fn6]</a></span> <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ040003?jcsearch=35%20U.S.C.252&amp;summary=yes#jcite">35 U.S.C. &sect; 252</a> provides, in relevant part:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The surrender of the original patent shall take effect upon the
issue of the reissued patent, and every reissued patent shall
have the same effect and operation in law, on the trial of
actions for causes thereafter arising, as if the same had been
originally granted in such amended form, but in so far as the
claims of the original and reissued patents are
<i>substantially identical</i>, such surrender shall not
affect any action then pending nor abate any cause of action
then existing, and the reissued patent, to the extent that its
claims are <i>substantially identical</i> with the original
patent, shall constitute a continuation thereof and have effect
continuously from the date of the original patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A reissued patent shall not abridge or affect the right of any
person or that person's successors in business who, prior to
the grant of a reissue, made, purchased, offered to sell, or
used within the United States, or imported into the United
States, anything patented by the reissued patent, to continue
the use of, to offer to sell, or to sell to others to be used,
offered for sale, or sold, the specific thing so made,
purchased, offered for sale, used, or imported unless the
making, using, offering for sale, or selling of such thing
infringes <i>a valid claim of the reissued patent which was in</i>
<i>the original patent.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn701" name="fn701">[fn7]</a></span> "Amend" is defined as "to change or alter in any way esp.
in phraseology." <i>Webster's Third New International</i>
<i>Dictionary</i> 57 (2000).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn801" name="fn801">[fn8]</a></span> The majority is correct that <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307&amp;summary=yes#jcite">section 307</a> contemplates
that an amended claim will be identified as such in the
reexamination certificate, but the failure of the PTO to
identify an amended claim as such can hardly bind absent
parties who had no opportunity to object to the PTO's failure,
especially given the "great principle of public policy . . .
which forbids that the public interests should be prejudiced by
the negligence of the officers or agents to whose care they are
confided." <i>Brock v. Pierce Cnty.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CB9D?jcsearch=476%20us%20253&amp;summary=yes#jcite">476 U.S. 253</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CB9D?jcsearch=476%20us%20253&amp;summary=yes#jcite">261</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CB9D?jcsearch=106%20supreme%20court%201834&amp;summary=yes#jcite">106 S.Ct. 1834</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CB9D?jcsearch=90%20l%20ed%202d%20248&amp;summary=yes#jcite">90 L.Ed.2d 248</a> (1986) (quoting <i>United</i>
<i>States v. Nashville, C. &amp; St. L.R. Co.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BCKR?jcsearch=118%20us%20120&amp;summary=yes#jcite">118 U.S. 120</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BCKR?jcsearch=118%20us%20120&amp;summary=yes#jcite">125</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BCKR?jcsearch=6%20supreme%20court%201006&amp;summary=yes#jcite">6 S.Ct. 1006</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5BCKR?jcsearch=30%20l%20ed%2081&amp;summary=yes#jcite">30 L.Ed. 81</a> (1886)). It is well established
that an administrative agency's failure to perform a prescribed
administrative act is not a ground for ignoring the substance
of the agency's action. <i>See United States v. James Daniel</i>
<i>Good Real Prop.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CCF9?jcsearch=510%20us%2043&amp;summary=yes#jcite">510 U.S. 43</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CCF9?jcsearch=510%20us%2043&amp;summary=yes#jcite">63</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CCF9?jcsearch=114%20supreme%20court%20492&amp;summary=yes#jcite">114 S.Ct. 492</a>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CCF9?jcsearch=126%20l%20ed%202d%20490&amp;summary=yes#jcite">126 L.Ed.2d 490</a> (1993) ("We have long recognized that many
statutory requisitions intended for the guide of officers in
the conduct of business devolved upon them . . . do not limit
their power or render its exercise in disregard of the
requisitions ineffectual." (internal quotation marks omitted));
<i>Brock</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CB9D?jcsearch=476%20us%20253&amp;summary=yes#jcite">476 U.S. at 261</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X5CB9D?jcsearch=106%20supreme%20court%201834&amp;summary=yes#jcite">106 S.Ct. 1834</a>; <i>Timken</i>
<i>U.S. Corp. v. United States</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12OAEQ003?jcsearch=421%20f%203d%201350&amp;summary=yes#jcite">421 F.3d 1350</a>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X12OAEQ003?jcsearch=421%20f%203d%201350&amp;summary=yes#jcite">1357</a> (Fed. Cir.
2005).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn901" name="fn901">[fn9]</a></span> <i>See</i> Maj. Op. at 1363 ("Whether or not Marine
Polymer's arguments to the examiner and cancellation of claims
during reexamination <i>may have affected the remaining</i>
<i>claims' effective scope</i>, they did not `amend' those claims
for intervening rights purposes. . . . HemCon sidesteps this
issue by emphasizing the <i>well-recognized principle that</i>
<i>arguments made during prosecution can affect the ultimate</i>
<i>meaning of a claim term</i> &mdash; <i>and thus the `scope'</i>
<i>of a claim.</i> . . . While it is true that <i>claims are</i>
<i>properly interpreted to account for arguments and concessions</i>
<i>made during prosecution</i>, HemCon's conclusion that the
claims asserted here were `amended' for purposes of
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XEJ06C003?jcsearch=35%20U.S.C.%20307(b)&amp;summary=yes#jcite">&sect; 307(b)</a> goes too far." (emphasis added)); <i>see also Am.</i>
<i>Piledriving Equip.</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1F5446003?jcsearch=637%20f%203d%201324&amp;summary=yes#jcite">637 F.3d at 1336</a>; <i>CIAS</i>,
<a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X17NN9G003?jcsearch=504%20f%203d%201356&amp;summary=yes#jcite">504 F.3d at 1362</a>; <i>C.R. Bard</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/XFPDCG?jcsearch=388%20f%203d%20858&amp;summary=yes#jcite">388 F.3d at 867-69</a>;
<i>Cole</i>, <a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X350N7?jcsearch=102%20f%203d%20524&amp;summary=yes#jcite">102 F.3d at 532</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1001" name="fn1001">[fn10]</a></span> While absolute intervening rights should exist here as a
matter of law, the issue of equitable intervening rights is a
fact intensive one, involving numerous issues to be considered
by the district court. Because the district court has not made
any factual findings with respect to equitable intervening
rights, this issue should be remanded to the district court for
its consideration in the first instance, as the original panel
ordered.
</p></div>
<!--BBLS DD 1694805983235-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HAD4U003/history">Direct History (23)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HAD4U003/analysis">Case Analysis (17)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HAD4U003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
17
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Biotechnology</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/97842979cc5469a61613094878bc7879/document/X1Q6LEB8CRO2">10-01548 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Damages &amp; Remedies</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/97842979cc5469a61613094878bc7879/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "97842979cc5469a61613094878bc7879";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY917b36&previousPageId=&previousActivityInstanceId=ENTITYaaa58b&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:38:51-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HAD4U003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYaaa58b&previousPageId=&previousActivityInstanceId=ENTITY3a8b34&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:38:44-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HAD4U003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HAD4U003";
$('#page_loader').show().spin();
JUDGE_IDS=["15753020","1718421","1850676","1910097","3027440","3027446","3057465","3408847","3496219","4063892","4141613","4283465"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
